PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
27063220-5	2016	Direct CYP inhibition was validated using 7 inhibitors (alpha-naphthoflavone, tranylcypromine, ticlopidine, fluconazole, quinidine, ketoconazole and 1-ABT).	Ticlopidine	95-106	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	7-10
28043905-16	2017	CONCLUSIONS: In a GWAS of persons of European descent with DILI, we associated HLA-A*33:01 with DILI due to terbinafine and possibly fenofibrate and ticlopidine.	Ticlopidine	149-160	major histocompatibility complex, class I, A	Homo sapiens	79-84
26412325-4	2015	The anticoagulant ticlopidine, which inhibits the purinergic receptor P2Y12, potentiated imipramine, elevating cAMP, a modulator of autophagy, reducing cell viability in culture, and increasing survival in glioma-bearing mice.	Ticlopidine	18-29	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	70-75
27386066-2	2016	It seems that methadone as CYP2C19 inhibitor affects ticlopidine activity in vivo.	Ticlopidine	53-64	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	27-34
24433137-2	2015	Ticlopidine was the first widely used P2Y12 receptor blockers, but clopidogrel has mostly replaced the use of ticlopidine due to its more favorable adverse event profile on bone marrow.	Ticlopidine	0-11	purinergic receptor P2Y12	Homo sapiens	38-43
26335194-4	2015	Ticlopidine, a CYP2B6 substrate, prevented the enzyme from the inactivation induced by PRN.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	15-21
25367325-4	2015	We report the case of a woman diagnosed with congenital TTP in her adulthood, presenting with anti-ADAMTS13 autoantibodies in acute phase during ticlopidine consumption.	Ticlopidine	145-156	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	99-107
26327247-5	2015	Moreover, ticlopidine induced severe hemorrhages and inhibited both blood and lymph vessel formation by modulating the expression of xMsr and Prox1 in Xenopus embryos.	Ticlopidine	10-21	apelin receptor S homeolog	Xenopus laevis	133-137
26327247-5	2015	Moreover, ticlopidine induced severe hemorrhages and inhibited both blood and lymph vessel formation by modulating the expression of xMsr and Prox1 in Xenopus embryos.	Ticlopidine	10-21	prospero homeobox 1 L homeolog	Xenopus laevis	142-147
26327247-6	2015	Additionally, Nkx2.5 and Cyl104 levels were perturbed by ticlopidine exposure, and more extensive aberrations were observed in the liver and heart using whole-mount in situ hybridization.	Ticlopidine	57-68	NK2 homeobox 5 S homeolog	Xenopus laevis	14-20
26327247-7	2015	In addition, ticlopidine reduced branching in HUVECs by blocking the effect of the angiogenic vascular endothelial growth factor (VEGF).	Ticlopidine	13-24	vascular endothelial growth factor A L homeolog	Xenopus laevis	94-128
26327247-7	2015	In addition, ticlopidine reduced branching in HUVECs by blocking the effect of the angiogenic vascular endothelial growth factor (VEGF).	Ticlopidine	13-24	vascular endothelial growth factor A L homeolog	Xenopus laevis	130-134
25787305-6	2015	Both dl-PHPB and ticlopidine (P2Y12 receptor antagonist) decreased cytoplasmic Ca(2+) concentration.	Ticlopidine	17-28	purinergic receptor P2Y12	Rattus norvegicus	30-35
25378064-8	2015	Ticlopidine, a substrate of CYP2B6, showed protection of the enzyme against the inactivation induced by IMP.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
24636274-0	2014	Transient receptor potential ankyrin 1 (TRPA1) channel activation by the thienopyridine-type drugs ticlopidine, clopidogrel, and prasugrel.	Ticlopidine	99-110	transient receptor potential cation channel subfamily A member 1	Homo sapiens	40-45
24855828-5	2014	Both ticlopidine and fluvoxamine were competitive inhibitors of CYP2C19.	Ticlopidine	5-16	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	64-71
24636274-7	2014	These findings indicate that a robust TRPA1 activation by ticlopidine and clopidogrel correlates with the stimulatory effect on the secretion of 5-HT.	Ticlopidine	58-69	transient receptor potential cation channel subfamily A member 1	Homo sapiens	38-43
24636274-8	2014	As recipients of ticlopidine and clopidogrel frequently complain about gastrointestinal adverse events such as nausea, vomiting and diarrhoea, an activation of TRPA1 may contribute to adverse effects of such drugs in the digestive system.	Ticlopidine	17-28	transient receptor potential cation channel subfamily A member 1	Homo sapiens	160-165
24170778-0	2014	Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine.	Ticlopidine	215-226	paraoxonase 1	Homo sapiens	121-134
24170778-0	2014	Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine.	Ticlopidine	215-226	carboxylesterase 1	Homo sapiens	139-157
25180024-3	2014	We previously observed that ticlopidine in its prodrug form, which does not affect P2 receptor activity, inhibited the recombinant form of human NTPDase1 (K i = 14 muM).	Ticlopidine	28-39	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	145-153
25180024-4	2014	Here we tested whether ticlopidine can be used as a selective inhibitor of NTPDase1.	Ticlopidine	23-34	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	75-83
25180024-0	2014	Ticlopidine in its prodrug form is a selective inhibitor of human NTPDase1.	Ticlopidine	0-11	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	66-74
25180024-5	2014	We confirmed that ticlopidine inhibits NTPDase1 in different forms and in different assays.	Ticlopidine	18-29	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	39-47
25180024-6	2014	The ADPase activity of intact HUVEC as well as of COS-7 cells transfected with human NTPDase1 was strongly inhibited by 100 microM ticlopidine, 99 and 86%, respectively.	Ticlopidine	131-142	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	85-93
25180024-7	2014	Ticlopidine (100 microM) completely inhibited the ATPase activity of NTPDase1 in situ as shown by enzyme histochemistry with human liver and pancreas sections.	Ticlopidine	0-11	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	69-77
25180024-8	2014	Ticlopidine also inhibited the activity of rat and mouse NTPDase1 and of potato apyrase.	Ticlopidine	0-11	ectonucleoside triphosphate diphosphohydrolase 1	Mus musculus	57-65
25180024-10	2014	Weak inhibition (10-20%) of NTPDase3 and -8 was observed at 1 mM ticlopidine.	Ticlopidine	65-76	ectonucleoside triphosphate diphosphohydrolase 3	Homo sapiens	28-36
25180024-11	2014	These results show that ticlopidine is a specific inhibitor of NTPDase1 that can be used in enzymatic and histochemistry assays.	Ticlopidine	24-35	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	63-71
23839753-7	2013	FINDINGS: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (eg, ticlopidine, clopidogrel, prasugrel, ticagrelor) reduces the risk of stent thrombosis and subsequent cardiovascular events post-PCI (number needed to treat, 33-53) and is the current standard of care.	Ticlopidine	76-87	purinergic receptor P2Y12	Homo sapiens	55-60
21546349-5	2011	Three isoenzyme-specific CYP inhibitors including alpha-naphthoflavone, ticlopidine, and ketoconazole that mainly target CYP1A, CYP2B/2C, and CYP3A, respectively, also enhanced the cytotoxicity.	Ticlopidine	72-83	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	25-28
23530950-0	2013	Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).	Ticlopidine	0-11	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	23-31
23635947-8	2013	Several HLA alleles also demonstrate drug-specific associations with DILI, such as HLA-A*33:03 for ticlopidine, HLA-B*57:01 for flucloxacillin and HLA-DQA1*02:01 for lapatinib.	Ticlopidine	99-110	major histocompatibility complex, class II, DQ alpha 1	Homo sapiens	8-11
23635947-8	2013	Several HLA alleles also demonstrate drug-specific associations with DILI, such as HLA-A*33:03 for ticlopidine, HLA-B*57:01 for flucloxacillin and HLA-DQA1*02:01 for lapatinib.	Ticlopidine	99-110	major histocompatibility complex, class I, A	Homo sapiens	83-88
23660864-0	2013	Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies.	Ticlopidine	65-76	complement factor H	Homo sapiens	11-19
23474500-4	2013	Specific mammalian inhibitors were used as diagnostic tools for related activities of CYP1A (alpha-naphthoflavone; alphaNF), CYP2B6 and CYP2C19 (ticlopidine) and CYP3A4 (ketoconazole).	Ticlopidine	145-156	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	136-143
24303458-2	2013	Ticlopidine induced TTP has been highly associated with autoimmune induced reduction in ADAMTS-13 activity.	Ticlopidine	0-11	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	88-97
23111862-6	2012	Severe deficiency of ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) was present in 80% and antibodies to 100% of these TTP patients on ticlopidine, 0% of the patients with clopidogrel-associated TTP (p < 0.05), and an unknown percentage of patients with prasugrel-associated TTP.	Ticlopidine	182-193	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	21-30
22906899-3	2012	P2Y(12) inhibitors include ticlopidine (now rarely used), clopidogrel, prasugrel, and ticagrelor.	Ticlopidine	27-38	purinergic receptor P2Y12	Homo sapiens	0-7
22918731-2	2012	Among the P2Y12 receptor inhibitors, the group of thienopyridines include ticlopidine, clopidogrel and prasugrel, all of which are orally administered prodrugs leading to irreversible P2Y12 receptor inhibition.	Ticlopidine	74-85	purinergic receptor P2Y12	Homo sapiens	10-15
22918731-2	2012	Among the P2Y12 receptor inhibitors, the group of thienopyridines include ticlopidine, clopidogrel and prasugrel, all of which are orally administered prodrugs leading to irreversible P2Y12 receptor inhibition.	Ticlopidine	74-85	purinergic receptor P2Y12	Homo sapiens	184-189
21822146-2	2011	We hypothesized that formation of thienopyridine-derived nitrosothiols (ticlopidine-SNO, clopidogrel-SNO, and prasugrel-SNO) occurs directly from the respective parent drug.	Ticlopidine	72-83	strawberry notch homolog 1	Homo sapiens	84-87
21832258-4	2011	The non-CYP3A4 inhibitors diethyldithiocarbamate, quercetin, quinidine, sulfaphenazole, ticlopidine, and tranylcypromine were found to have substantially lower (maximum inhibition of <50%) or no apparent inhibitory effects in the HTS assay.	Ticlopidine	88-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-14
21570381-5	2011	The selective inhibitors of CYP2B6 (ticlopidine and phencyclidine) and monoclonal antibodies raised against human CYP2B6 isozyme caused 80% inhibition of OH-BUP formation by baboon hepatic microsomes.	Ticlopidine	36-47	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
22963529-2	2013	The first family of adenosine diphosphate P2Y12 receptors inhibiting drug is represented by thienopyridines and among these ticlopidine was the first approved by Food and Drug Administration; actually its use is discouraged because of its potential side effects (neutropenia, anemia, gastrointestinal distress and thrombotic thrombocytopenic purpura).	Ticlopidine	124-135	purinergic receptor P2Y12	Homo sapiens	42-47
23099620-1	2013	PURPOSE: We assessed possible drug interactions of tramadol given concomitantly with the potent CYP2B6 inhibitor ticlopidine, alone or together with the potent CYP3A4 and P-glycoprotein inhibitor itraconazole.	Ticlopidine	113-124	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	96-102
23099620-7	2013	CONCLUSIONS: Ticlopidine increased exposure to tramadol, reduced its renal clearance and inhibited the formation of M1, most likely via inhibition of CYP2B6 and/or CYP2D6.	Ticlopidine	13-24	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	150-156
23099620-7	2013	CONCLUSIONS: Ticlopidine increased exposure to tramadol, reduced its renal clearance and inhibited the formation of M1, most likely via inhibition of CYP2B6 and/or CYP2D6.	Ticlopidine	13-24	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	164-170
23361846-2	2013	This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.	Ticlopidine	197-208	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	46-52
23361846-2	2013	This investigation tested the hypothesis that CYP2B6 is a prominent CYP isoform responsible for clinical methadone N-demethylation and clearance, using the in vivo mechanism-based CYP2B6 inhibitor ticlopidine, given orally for 4 days.	Ticlopidine	197-208	peptidylprolyl isomerase G	Homo sapiens	46-49
22651985-8	2012	Pre-incubation with recombinant human CYP3A4 not only caused degradation of clopidogrel and ticlopidine, but also increased cytotoxicity.	Ticlopidine	92-103	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
22651985-10	2012	Pre-incubation with freshly isolated human granulocytes was not only associated with a myeloperoxidase-dependent degradation of clopidogrel, clopidogrel carboxylate and ticlopidine, but also with dose-dependent cytotoxicity of these compounds starting at 10 muM.	Ticlopidine	169-180	myeloperoxidase	Homo sapiens	87-102
22651985-13	2012	Concerning ticlopidine, both the parent compound and metabolites formed by myeloperoxidase may be myelotoxic in vivo.	Ticlopidine	11-22	myeloperoxidase	Homo sapiens	75-90
22652334-3	2012	To distinguish reversible MDI from mechanism-based inhibition (MBI), R-fluoxetine and ticlopidine were used as positive inhibitors for reversible MDI and MBI of CYP2C19, respectively.	Ticlopidine	86-97	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	161-168
22652334-4	2012	R-fluoxetine and ticlopidine inhibited CYP2C19 activity, as determined using S-mephenytoin as a substrate, and caused 8.7- and 2.3-fold IC(50) shifts, respectively, after pre-incubation.	Ticlopidine	17-28	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	39-46
22360514-2	2012	Ticlopidine, Clopidogrel, Prasugrel, Ticagrelor, Cangrelor and Elinogrel are the P2Y12 inhibitors that act as antiplatelet drugs.	Ticlopidine	0-11	purinergic receptor P2Y12	Homo sapiens	81-86
21946108-1	2011	Thienopyridines (ticlopidine, clopidogrel and prasugrel) are pro-drugs that require metabolism to exhibit a critical thiol group in the active form that binds to the P2Y12 receptor to inhibit platelet activation and prevent thrombus formation in vivo.	Ticlopidine	17-28	purinergic receptor P2Y12	Homo sapiens	166-171
21716267-1	2011	This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole.	Ticlopidine	107-118	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	71-96
21546349-5	2011	Three isoenzyme-specific CYP inhibitors including alpha-naphthoflavone, ticlopidine, and ketoconazole that mainly target CYP1A, CYP2B/2C, and CYP3A, respectively, also enhanced the cytotoxicity.	Ticlopidine	72-83	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	142-147
21554368-10	2011	P2Y12 is the same receptor targeted by ticlopidine and clopidogrel, platelet inhibitors used in lieu of aspirin in people at risk for cardiovascular disease; thus, spontaneous bleeding is not expected unless there are other contributing factors.	Ticlopidine	39-50	purinergic receptor P2Y12	Homo sapiens	0-5
21666702-8	2011	Ticlopidine inhibited CYP2C9 and 3A4 with IC50 values of 26.0 and 32.3 mumol/L, respectively.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	22-28
21666702-10	2011	CONCLUSION: The significant increase in the AUC of losartan (9 mg/kg) by ticlopidine (10 mg/kg) could be attributed to the inhibition of CYP2C9- and 3A4-mediated losartan metabolism in small intestine and/or in liver.	Ticlopidine	73-84	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	137-143
21156812-0	2011	Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.	Ticlopidine	37-48	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	58-77
21148250-8	2011	The recombinant human CYP2C19 inactivation kinetics of isoniazid, ticlopidine, and tranylcypromine were evaluated, and their key kinetic parameters were measured from the same experiment.	Ticlopidine	66-77	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	22-29
21156812-0	2011	Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.	Ticlopidine	37-48	cytochrome P450 2B4	Oryctolagus cuniculus	89-108
21156812-1	2011	A recent X-ray crystal structure of a rabbit cytochrome P450 2B4 (CYP2B4)-ticlopidine complex indicated that the compound could be modeled with either the thiophene or chlorophenyl group oriented toward the heme prosthetic group.	Ticlopidine	74-85	cytochrome P450 2B4	Oryctolagus cuniculus	45-64
21156812-1	2011	A recent X-ray crystal structure of a rabbit cytochrome P450 2B4 (CYP2B4)-ticlopidine complex indicated that the compound could be modeled with either the thiophene or chlorophenyl group oriented toward the heme prosthetic group.	Ticlopidine	74-85	cytochrome P450 2B4	Oryctolagus cuniculus	66-72
21156812-3	2011	To evaluate the predictive value of these findings, the oxidation of ticlopidine by reconstituted CYP2B4 was studied and compared with CYP2B6, in which the thiophene portion of the molecule likely orients toward the heme.	Ticlopidine	69-80	cytochrome P450 2B4	Oryctolagus cuniculus	98-104
21156812-7	2011	However, the amplitude (R(max)) of M1 and M6 formation was 4 to 5 times higher for CYP2B6 than CYP2B4, indicating a greater residence time of ticlopidine with its thiophene ring closer to heme in CYP2B6.	Ticlopidine	142-153	cytochrome P450 2B4	Oryctolagus cuniculus	95-101
21156812-9	2011	Overall, the results suggest that the preferential orientation of ticlopidine in the active site of CYP2B4 predicted by X-ray crystallography and NMR studies is unproductive and that ticlopidine likely reorients within CYP2B4 to a more productive mode.	Ticlopidine	66-77	cytochrome P450 2B4	Oryctolagus cuniculus	100-106
21156812-9	2011	Overall, the results suggest that the preferential orientation of ticlopidine in the active site of CYP2B4 predicted by X-ray crystallography and NMR studies is unproductive and that ticlopidine likely reorients within CYP2B4 to a more productive mode.	Ticlopidine	183-194	cytochrome P450 2B4	Oryctolagus cuniculus	219-225
20610889-0	2010	Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese.	Ticlopidine	40-51	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	92-98
21178986-0	2011	Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.	Ticlopidine	98-109	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	24-31
21178986-6	2011	Ticlopidine may be an effective therapeutic option for CYP2C19 PMs.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	55-62
20854995-12	2010	Microsomal cytochrome P450 2C activity was inhibited by treatment with curcumin or ticlopidine, whereas cytochrome P450 3A activity was inhibited by treatment with curcumin or diltiazem.	Ticlopidine	83-94	cytochrome P450, family 2, subfamily C, polypeptide 19	Bos taurus	11-29
20977463-1	2010	BACKGROUND AND PURPOSE: After conversion to their active forms by the liver, ticlopidine and clopidogrel exert antiplatelet effects through irreversible inhibition of the P2Y12 receptor.	Ticlopidine	77-88	purinergic receptor P2Y12	Homo sapiens	171-176
20977463-8	2010	Accordingly, these compounds showed a mixed-type inhibition of recombinant human NTPDase1 with an apparent K(i) (K(i,app) ) of 10 microM (clopidogrel) and 14 microM (ticlopidine).	Ticlopidine	166-177	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	81-89
20977463-9	2010	Recombinant rat ecto-5"-nucleotidase, but not its human orthologue, was inhibited by ticlopidine with a K(i,app) of 4.5 mM.	Ticlopidine	85-96	5' nucleotidase, ecto	Rattus norvegicus	16-36
19948947-7	2010	Knowledge of the CYP-dependent formation of ticlopidine and clopidogrel thiolactones helps explain some of the observed drug-drug interactions with these molecules and, more important, the role of CYP2C19 genetic polymorphism on the pharmacokinetics of and pharmacodynamic response to clopidogrel.	Ticlopidine	44-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	197-204
20610889-2	2010	We investigated the relationship between CYP2B6 haplotype and incidence of TP-induced hepatotoxicity in 114 Japanese patients.	Ticlopidine	75-77	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	41-47
20831051-2	2010	In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives.	Ticlopidine	188-199	purinergic receptor P2Y12	Homo sapiens	130-135
19047469-0	2009	Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.	Ticlopidine	59-70	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	36-55
20081260-0	2009	Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes.	Ticlopidine	43-54	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	58-64
20081260-4	2009	A comparative in vitro study provides clear evidence that ticlopidine and DDC, applied at concentrations that inhibit the above-mentioned CYP isoforms, potently (as compared to furafylline) inhibit human CYP1A2 and caffeine metabolism, in particular 1-N- and 3-N-demethylation.	Ticlopidine	58-69	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	138-141
20081260-4	2009	A comparative in vitro study provides clear evidence that ticlopidine and DDC, applied at concentrations that inhibit the above-mentioned CYP isoforms, potently (as compared to furafylline) inhibit human CYP1A2 and caffeine metabolism, in particular 1-N- and 3-N-demethylation.	Ticlopidine	58-69	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	204-210
19288055-7	2009	Her symptoms were reduced firstly using acetylsalicylic acid, then ticlopidine 250 mg bid was begun and then Pentoxyphillin, resulting in a significant improvement of symptoms with the disappearance of headache.	Ticlopidine	67-78	BH3 interacting domain death agonist	Homo sapiens	86-89
19144769-4	2009	In this study, we compared fluoxetine, its (R)- and (S)-enantiomers, ticlopidine, and S-benzylnirvanol as potential time-dependent inhibitors of human liver microsomal CYP2C19.	Ticlopidine	69-80	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	168-175
19845434-0	2009	Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.	Ticlopidine	74-85	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	50-70
19845434-1	2009	Mechanism-based inhibition of CYP2C19 in human liver microsomes by the thienopyridine antiplatelet agents clopidogrel, prasugrel and their thiolactone metabolites was investigated by determining the time- and concentration-dependent inhibition of the activity of S-mephenytoin 4"-hydroxylase as typical CYP2C19 activity and compared with ticlopidine and its metabolite.	Ticlopidine	338-349	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	30-37
19845434-2	2009	Clopidogrel was shown to be a mechanism-based inhibitor of CYP2C19 with the inactivation kinetic parameters, k(inact) and K(I), equal to 0.0557 min(-1) and 14.3 microM, respectively, as well as ticlopidine (0.0739 min(-1) and 3.32 microM, respectively).	Ticlopidine	194-205	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	59-66
19845434-3	2009	The thiolactone metabolite of ticlopidine and clopidogrel inhibited CYP2C19 only in a concentration-dependent manner.	Ticlopidine	30-41	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	68-75
19047469-1	2009	Mechanism-based inhibition of CYP2B6 in human liver microsomes by thienopyridine antiplatelet agents ticlopidine and clopidogrel and the thiolactone metabolites of those two agents plus that of prasugrel were investigated by determining the time- and concentration-dependent inhibition of the activity of bupropion hydroxylase as the typical CYP2B6 activity.	Ticlopidine	101-112	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36
19047469-4	2009	In conclusion, ticlopidine, its thiolactone metabolite, and clopidogrel were more potent mechanism-based inhibitors of CYP2B6 than the thiolactone metabolite of prasugrel.	Ticlopidine	15-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	119-125
19334620-1	2009	The key role in platelet aggregation is played by the platelet ADP receptor P2Y12, which is the target for antiaggregant drugs, clopidogrel and ticlopidine.	Ticlopidine	144-155	purinergic receptor P2Y12	Homo sapiens	76-81
20069129-0	2009	Reduction of monocyte chemoattractant protein-1 and interleukin-8 levels by ticlopidine in TNF-alpha stimulated human umbilical vein endothelial cells.	Ticlopidine	76-87	C-C motif chemokine ligand 2	Homo sapiens	13-47
20069129-8	2009	These results suggest that ticlopidine decreased TNF-alpha induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion.	Ticlopidine	27-38	C-X-C motif chemokine ligand 8	Homo sapiens	74-78
19180126-3	2009	Ironically, use of anti-platelet agents, the thienopyridine derivates clopidogrel and ticlopidine, is associated with drug induced TTP.	Ticlopidine	86-97	ZFP36 ring finger protein	Homo sapiens	131-134
19180126-5	2009	Ticlopidine and clopidogrel are the two most common drugs associated with TTP in FDA safety databases.	Ticlopidine	0-11	ZFP36 ring finger protein	Homo sapiens	74-77
19402342-1	2009	A sensitive, selective and simple high performance liquid chromatographyelectrospray ionization-mass spectrometry (HPLC-ESI-MS) was developed and validated for the quantification of ticlopidine hydrochloride (CAS 53885-35-1) in human plasma using loratadine (CAS 79794-75-5) as internal standard (IS).	Ticlopidine	182-207	BCAR1 scaffold protein, Cas family member	Homo sapiens	209-212
19402342-1	2009	A sensitive, selective and simple high performance liquid chromatographyelectrospray ionization-mass spectrometry (HPLC-ESI-MS) was developed and validated for the quantification of ticlopidine hydrochloride (CAS 53885-35-1) in human plasma using loratadine (CAS 79794-75-5) as internal standard (IS).	Ticlopidine	182-207	BCAR1 scaffold protein, Cas family member	Homo sapiens	259-262
20069129-8	2009	These results suggest that ticlopidine decreased TNF-alpha induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion.	Ticlopidine	27-38	vascular cell adhesion molecule 1	Homo sapiens	84-90
20069129-0	2009	Reduction of monocyte chemoattractant protein-1 and interleukin-8 levels by ticlopidine in TNF-alpha stimulated human umbilical vein endothelial cells.	Ticlopidine	76-87	C-X-C motif chemokine ligand 8	Homo sapiens	52-65
20069129-0	2009	Reduction of monocyte chemoattractant protein-1 and interleukin-8 levels by ticlopidine in TNF-alpha stimulated human umbilical vein endothelial cells.	Ticlopidine	76-87	tumor necrosis factor	Homo sapiens	91-100
20069129-5	2009	In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF-alpha-stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs).	Ticlopidine	29-40	tumor necrosis factor	Mus musculus	99-108
20069129-5	2009	In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF-alpha-stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs).	Ticlopidine	29-40	chemokine (C-C motif) ligand 2	Mus musculus	120-125
20069129-5	2009	In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF-alpha-stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs).	Ticlopidine	29-40	chemokine (C-X-C motif) ligand 15	Mus musculus	127-131
20069129-5	2009	In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF-alpha-stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs).	Ticlopidine	29-40	vascular cell adhesion molecule 1	Mus musculus	137-170
20069129-5	2009	In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF-alpha-stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs).	Ticlopidine	29-40	vascular cell adhesion molecule 1	Mus musculus	172-178
20069129-8	2009	These results suggest that ticlopidine decreased TNF-alpha induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion.	Ticlopidine	27-38	tumor necrosis factor	Homo sapiens	49-58
20069129-8	2009	These results suggest that ticlopidine decreased TNF-alpha induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion.	Ticlopidine	27-38	C-C motif chemokine ligand 2	Homo sapiens	67-72
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
19463124-3	2009	In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives.	Ticlopidine	188-199	purinergic receptor P2Y12	Homo sapiens	130-135
19845526-3	2009	In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives.	Ticlopidine	188-199	purinergic receptor P2Y12	Homo sapiens	130-135
20038285-3	2009	In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives.	Ticlopidine	188-199	purinergic receptor P2Y12	Homo sapiens	130-135
20038286-3	2009	In a series of articles the authors consider clinical pharmacology and experience of clinical application of blockers of platelet P2Y12 receptors, most well known representatives of which ticlopidine and clopidogrel according to chemical structure belong to thienopyridine derivatives.	Ticlopidine	188-199	purinergic receptor P2Y12	Homo sapiens	130-135
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	277-283
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	285-291
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	293-299
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	301-307
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	309-316
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	318-324
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	326-332
18474675-2	2008	Mechanism-based CYP2B6 inhibitors (i.e., clopidogrel, ticlopidine, and triethylenethiophoramide) significantly inhibited the formation of M1 from sibutramine and M2 from M1, respectively; in contrast, no effect was observed when using potent inhibitors of eight P450 isozymes (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).	Ticlopidine	54-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	338-343
17332142-7	2007	In HLMs, analysis of the two-enzyme kinetics in the presence of P450 isozyme-selective chemical inhibitors (ticlopidine for CYP2C19, sulfaphenazole for CYP2C9, and furafylline for CYP1A2) indicated that CYP2C19 was the high affinity component and CYP2C9 was the low affinity component.	Ticlopidine	108-119	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	124-131
17339877-2	2008	There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01).	Ticlopidine	44-55	major histocompatibility complex, class II, DR beta 1	Homo sapiens	113-116
17339877-2	2008	There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01).	Ticlopidine	44-55	major histocompatibility complex, class I, A	Homo sapiens	127-132
18197559-11	2008	TSIIA was metabolized by rat CYP2C, 3A and 2D, as ticlopidine, ketoconazole and quinidine all inhibited TSIIA metabolism in rat liver microsomes.	Ticlopidine	50-61	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	29-45
19122335-2	2008	Ticlopidine and clopidogrel inhibited CYP2B6 with IC(50) values of 0.0517+/-0.0323 microM and 0.0182+/-0.0069 microM, respectively, and inhibited CYP2C19 with IC(50) values of 0.203+/-0.124 microM and 0.524+/-0.160 microM, respectively.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	38-44
19122335-2	2008	Ticlopidine and clopidogrel inhibited CYP2B6 with IC(50) values of 0.0517+/-0.0323 microM and 0.0182+/-0.0069 microM, respectively, and inhibited CYP2C19 with IC(50) values of 0.203+/-0.124 microM and 0.524+/-0.160 microM, respectively.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	146-153
19122335-3	2008	Ticlopidine also inhibited CYP2D6 (IC(50) of 0.354+/-0.158 microM).	Ticlopidine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	27-33
17682072-3	2007	In this report, we describe the selectivity of 2-phenyl-2-(1-piperidinyl)propane (PPP) as an inactivator of CYP2B6 and compare this selectivity versus other CYP2B6 inactivators: 1,1",1""-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine.	Ticlopidine	250-261	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	108-114
17339877-2	2008	There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01).	Ticlopidine	44-55	major histocompatibility complex, class I, B	Homo sapiens	139-144
17339877-2	2008	There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01).	Ticlopidine	44-55	major histocompatibility complex, class II, DR beta 1	Homo sapiens	127-130
17339877-2	2008	There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01).	Ticlopidine	44-55	major histocompatibility complex, class II, DR beta 1	Homo sapiens	164-172
17339877-2	2008	There was a significant correlation between ticlopidine-induced hepatotoxicity and five human leukocyte antigen (HLA) alleles: HLA-A*3303, HLA-B*4403, HLA-Cw*1403, HLA-DRB1*1302 and HLA-DQB1*0604 (corrected probability (P)-value (Pc)<0.01).	Ticlopidine	44-55	major histocompatibility complex, class II, DQ beta 1	Homo sapiens	182-190
17339877-3	2008	In particular HLA-A*3303 was present in 15 (68%) of the 22 patients with ticlopidine-induced hepatotoxicity and in 12 (14%) of the 85 ticlopidine-tolerant patients (odds ratio, 13.04; 95% confidence interval (CI), 4.40-38.59; the corrected P-value (Pc)=1.24 x 10(-5)).	Ticlopidine	73-84	major histocompatibility complex, class I, A	Homo sapiens	14-19
17339877-3	2008	In particular HLA-A*3303 was present in 15 (68%) of the 22 patients with ticlopidine-induced hepatotoxicity and in 12 (14%) of the 85 ticlopidine-tolerant patients (odds ratio, 13.04; 95% confidence interval (CI), 4.40-38.59; the corrected P-value (Pc)=1.24 x 10(-5)).	Ticlopidine	134-145	major histocompatibility complex, class I, A	Homo sapiens	14-19
17339877-4	2008	HLA-A*3303 was present in 12 (86%) of the 14 patients with ticlopidine-induced cholestatic hepatotoxicity (odds ratio, 36.50; 95% CI, 7.25-183.82, Pc=7.32 x 10(-7)).	Ticlopidine	59-70	major histocompatibility complex, class I, A	Homo sapiens	0-5
17339877-5	2008	Ticlopidine-induced severe cholestatic hepatotoxicity occurred more frequently in subjects with HLA-A*3303 and its haplotype in Japanese patients.	Ticlopidine	0-11	major histocompatibility complex, class I, A	Homo sapiens	96-101
17868804-7	2007	Compared with TTP patients with ADAMTS13 activity >15% (n = 13), TTP patients with severely deficient ADAMTS13 activity (n = 26) were more likely to have received ticlopidine (92.3% vs. 46.2%, p < 0.003).	Ticlopidine	166-177	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	105-113
17174298-9	2007	Importantly, acetylcholine-induced vasodilation in isolated aorta was improved in ticlopidine-treated apoE/LDLR(-/-) mice as compared to their non-treated counterparts.	Ticlopidine	82-93	low density lipoprotein receptor	Mus musculus	107-111
17307149-2	2007	In order to gain insights for developing personalized drugs, the 3D (dimensional) structure of CYP2C19 has been developed based on the crystal structure of CYP2C9 (PDB code 1R90), and its structure-activity relationship with the ligands of CEC, Fluvoxamine, Lescol, and Ticlopidine investigated through the structure-activity relationship approach.	Ticlopidine	270-281	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	95-102
17307149-2	2007	In order to gain insights for developing personalized drugs, the 3D (dimensional) structure of CYP2C19 has been developed based on the crystal structure of CYP2C9 (PDB code 1R90), and its structure-activity relationship with the ligands of CEC, Fluvoxamine, Lescol, and Ticlopidine investigated through the structure-activity relationship approach.	Ticlopidine	270-281	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	156-162
17174298-0	2007	Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.	Ticlopidine	0-11	apolipoprotein E	Mus musculus	57-73
17174298-10	2007	In conclusion, ticlopidine attenuates the progression of atherosclerosis and improves the endothelial function in apoE/LDLR(-/-) mice.	Ticlopidine	15-26	apolipoprotein E	Mus musculus	114-118
17174298-0	2007	Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.	Ticlopidine	0-11	low density lipoprotein receptor	Mus musculus	78-110
17174298-10	2007	In conclusion, ticlopidine attenuates the progression of atherosclerosis and improves the endothelial function in apoE/LDLR(-/-) mice.	Ticlopidine	15-26	low density lipoprotein receptor	Mus musculus	119-123
17174298-7	2007	However, the size of atherosclerotic plaques measured in aortic roots by the cross-section method and the number of macrophages estimated by anti-CD68 staining were significantly reduced by ticlopidine treatment.	Ticlopidine	190-201	CD68 antigen	Mus musculus	146-150
17187456-3	2007	The thienopyridine ticlopidine, an antagonist of the platelet P2Y12 ADP receptor, reduces the incidence of vascular events in patients at risk, but it also has some important drawbacks: a relatively high incidence of toxic effects; delayed onset of action; high inter-individual variability in response.	Ticlopidine	19-30	purinergic receptor P2Y12	Homo sapiens	62-67
17174298-9	2007	Importantly, acetylcholine-induced vasodilation in isolated aorta was improved in ticlopidine-treated apoE/LDLR(-/-) mice as compared to their non-treated counterparts.	Ticlopidine	82-93	apolipoprotein E	Mus musculus	102-106
17429206-3	2007	The antiplatelet effect of cyclooxygenase-1 inhibitors lasts less than 4 h. Skin and colonic bleeding times are prolonged for 3 and 5 days after aspirin and ticlopidine withdrawal respectively.	Ticlopidine	157-168	prostaglandin-endoperoxide synthase 1	Homo sapiens	27-43
16855053-4	2006	Ticlopidine (5 microM), a potent CYP2B6 inhibitor, and ketoconazole (10 microM), a selective CYP3A4 inhibitor, together inhibited approximately 90% of endosulfan-alpha metabolism in HLMs.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	33-39
17073575-8	2006	With validated in vitro and in vivo substrates (e.g. bupropion) and inhibitors (e.g. ticlopidine), it is expected that pharmacological (including pharmacogenetic) and clinical significance of CYP2B6 will be delineated more fully in the near future.	Ticlopidine	85-96	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	192-198
16855053-6	2006	In five of the six HLMs used, the percentage inhibition with ticlopidine and ketoconazole in the same incubation correlated with the combined % TNRs for CYP2B6 and CYP3A4.	Ticlopidine	61-72	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	153-159
16855053-6	2006	In five of the six HLMs used, the percentage inhibition with ticlopidine and ketoconazole in the same incubation correlated with the combined % TNRs for CYP2B6 and CYP3A4.	Ticlopidine	61-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	164-170
16724927-7	2006	Also, this is the first report that identifies several potent compounds that have the ability to transactivate hPXR that previously have not been identified, such as terbinafine, diclofenac, sildenafil, glimepiride, montelukast, and ticlopidine.	Ticlopidine	233-244	nuclear receptor subfamily 1 group I member 2	Homo sapiens	111-115
15955565-5	2005	Due to its central role in the formation and stabilization of a thrombus, the P2Y12 receptor is a well-established target of antithrombotic drugs like ticlopidine or clopidogrel, which have proved efficacy in many clinical trials and experimental models of thrombosis.	Ticlopidine	151-162	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	78-83
16368572-8	2006	Advances in understanding the importance of the P2Y12 receptor has resulted in the development of drugs like clopidogrel and ticlopidine that is being successfully used clinically in the treatment of thrombotic disorders.	Ticlopidine	125-136	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	48-53
16388413-4	2005	Autoantibodies against ADAMTS13 were present in majority of patients with idiopathic TTP and ticlopidine- and clopidogrel-associated TTP.	Ticlopidine	93-104	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	23-31
16272957-0	2005	Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status.	Ticlopidine	64-75	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	91-98
16272957-1	2005	OBJECTIVES: The aim of this study was to investigate the impact of CYP2C19 polymorphism on the extent of the interaction and on the pharmacokinetics and pharmacodynamics of ticlopidine.	Ticlopidine	173-184	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	67-74
16272957-9	2005	CONCLUSIONS: Ticlopidine is a potent inhibitor for CYP2C19 and may be associated with the phenocopy when CYPC19 substrates are co-administered to EMs.	Ticlopidine	13-24	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	51-58
16272957-10	2005	Whether and to what extent CYP2C19 would be involved in the metabolism of ticlopidine remain unanswered from the present in-vivo study.	Ticlopidine	74-85	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	27-34
16282990-1	2005	We studied the effect of vasopressin analogue desglycinamide-arginine-vasopressin on changes in platelet hemostasis produced by intragastric administration of Ticlid or clopidogrel (inhibitors of ADP-induced platelet aggregation).	Ticlopidine	159-165	arginine vasopressin	Homo sapiens	25-36
15609708-0	2004	POEMS syndrome demonstrating VEGF decrease by ticlopidine.	Ticlopidine	46-57	vascular endothelial growth factor A	Homo sapiens	29-33
15961986-0	2005	Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.	Ticlopidine	26-37	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	41-60
15961986-1	2005	OBJECTIVE: Our objective was to study the effect of the antiplatelet agents clopidogrel and ticlopidine on bupropion (INN, amfebutamone) hydroxylation, a probe reaction for cytochrome P450 (CYP) 2B6 activity.	Ticlopidine	92-103	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	173-198
15961986-8	2005	CONCLUSIONS: Both clopidogrel and ticlopidine significantly inhibited the CYP2B6-catalyzed bupropion hydroxylation.	Ticlopidine	34-45	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	74-80
15961986-9	2005	Patients receiving either clopidogrel or ticlopidine are likely to require dose adjustments when treated with drugs primarily metabolized by CYP2B6.	Ticlopidine	41-52	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	141-147
15816504-3	2005	However, the agents currently on the market (ticlopidine and clopidogrel), or known to be in development (cangrelor, AZD-6140 and prasugrel), all target the P2Y12 receptor.	Ticlopidine	45-56	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	157-162
15816504-4	2005	The thienopyridines (ticlopidine, clopidogrel and prasugrel) irreversibly inactivate the P2Y12 receptor via the covalent binding of an active metabolite generated in the liver, while the other compounds are competitive antagonists.	Ticlopidine	21-32	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	89-94
16245416-3	2005	Its mode of action has not been defined, but it appears that metabolites of ticlopidine are antagonists of the platelet ADP receptor.	Ticlopidine	76-87	purinergic receptor P2Y12	Homo sapiens	111-132
16104532-11	2005	These results suggest that ticlopidine or its metabolites induce the production of autoantibodies against ADAMTS13.	Ticlopidine	27-38	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	106-114
15670026-8	2005	Restenosis (stent 26%; balloon 38%) was significantly correlated to an attenuated PAI-1 increase after 24 h in the ticlopidine group (P = 0.007; restenosis, relative Delta PAI-1 + 50 +/- 28%; non-restenosis, + 139 +/- 50%), but not in the coumadin group.	Ticlopidine	115-126	serpin family E member 1	Homo sapiens	82-87
15670026-8	2005	Restenosis (stent 26%; balloon 38%) was significantly correlated to an attenuated PAI-1 increase after 24 h in the ticlopidine group (P = 0.007; restenosis, relative Delta PAI-1 + 50 +/- 28%; non-restenosis, + 139 +/- 50%), but not in the coumadin group.	Ticlopidine	115-126	serpin family E member 1	Homo sapiens	172-177
15670026-10	2005	ISR in ticlopidine-treated patients was associated with an attenuated early PAI-1 active antigen increase.	Ticlopidine	7-18	serpin family E member 1	Homo sapiens	76-81
15609708-6	2004	Although administration of aspirin did not decrease VEGF, ticlopidine decreased VEGF significantly.	Ticlopidine	58-69	vascular endothelial growth factor A	Homo sapiens	80-84
15155554-7	2004	In addition to CYP2B6, ticlopidine also inhibited both mephenytoin 4-hydroxylation (CYP2C19) (IC(50), 2.7 microM) and dextromethorphan O-demethylation (CYP2D6) (IC(50), 4.4 microM).	Ticlopidine	23-34	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	84-91
15155554-7	2004	In addition to CYP2B6, ticlopidine also inhibited both mephenytoin 4-hydroxylation (CYP2C19) (IC(50), 2.7 microM) and dextromethorphan O-demethylation (CYP2D6) (IC(50), 4.4 microM).	Ticlopidine	23-34	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	152-158
14977868-8	2004	Ticlopidine, a CYP2C19 mechanism-based inhibitor, inhibited disulfoton sulfoxidation by CYP2C19 (IC50 after coincubation, 43.5 microM; IC50 after preincubation, 4.3 microM) and also in HLMs.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	15-22
15056479-4	2004	alpha-Naphthoflavone (a CYP1A2 inhibitor) and ketoconazole (a CYP3A4 inhibitor) significantly decreased the rate of perazine 5-sulphoxidation, while ticlopidine (a CYP2C19 inhibitor) strongly reduced the rate of perazine N-demethylation in human liver microsomes.	Ticlopidine	149-160	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	164-171
15094937-5	2004	After administration of ticlopidine, platelet-derived microparticles and activated platelets corrected positively, not only CD62P- and CD63-positive platelets, but also platelet-derived microparticles and monocyte-derived microparticles showed a significant decrease.	Ticlopidine	24-35	selectin P	Homo sapiens	124-129
15094937-5	2004	After administration of ticlopidine, platelet-derived microparticles and activated platelets corrected positively, not only CD62P- and CD63-positive platelets, but also platelet-derived microparticles and monocyte-derived microparticles showed a significant decrease.	Ticlopidine	24-35	CD63 molecule	Homo sapiens	135-139
14977868-8	2004	Ticlopidine, a CYP2C19 mechanism-based inhibitor, inhibited disulfoton sulfoxidation by CYP2C19 (IC50 after coincubation, 43.5 microM; IC50 after preincubation, 4.3 microM) and also in HLMs.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	88-95
14717977-1	2004	The P2Y12 ADP receptor is one of the major regulators of platelet activation and the target of antithrombotic thienopyridines (ticlopidine and clopidogrel).	Ticlopidine	127-138	purinergic receptor P2Y12	Homo sapiens	4-9
14687031-2	2004	Severe deficiency of disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS13), described in familial cases and a significant fraction of idiopathic TTP, has been reported in only a few ticlopidine-linked cases.	Ticlopidine	202-213	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	85-93
14687031-6	2004	In parallel, ticlopidine and plasmas from idiopathic and ticlopidine-TTP patients decreased transcripts for the ECM component thrombospondin-1 in MVEC, but not in large vessel EC.	Ticlopidine	13-24	thrombospondin 1	Homo sapiens	126-142
14687031-6	2004	In parallel, ticlopidine and plasmas from idiopathic and ticlopidine-TTP patients decreased transcripts for the ECM component thrombospondin-1 in MVEC, but not in large vessel EC.	Ticlopidine	57-68	thrombospondin 1	Homo sapiens	126-142
14687031-8	2004	Induction of apoptosis by ticlopidine and TTP plasma was abrogated by inhibitors of ERK-1/2 and p38 phosphorylation.	Ticlopidine	26-37	mitogen-activated protein kinase 3	Homo sapiens	84-91
14687031-8	2004	Induction of apoptosis by ticlopidine and TTP plasma was abrogated by inhibitors of ERK-1/2 and p38 phosphorylation.	Ticlopidine	26-37	mitogen-activated protein kinase 1	Homo sapiens	96-99
14563790-0	2004	Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.	Ticlopidine	69-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	43-49
14563790-4	2004	Both clopidogrel and ticlopidine inhibited CYP2B6 with highest potency and CYP2C19 with lower potency.	Ticlopidine	21-32	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	43-49
14563790-4	2004	Both clopidogrel and ticlopidine inhibited CYP2B6 with highest potency and CYP2C19 with lower potency.	Ticlopidine	21-32	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	75-82
14563790-5	2004	Clopidogrel also inhibited CYP2C9, and ticlopidine also inhibited CYP1A2, with lower potency.	Ticlopidine	39-50	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	66-72
12913786-4	2003	P2Y(12) is the target of antithrombotic drugs (ticlopidine, clopidogrel), whereas the role of P2Y(1) in thrombosis remains to be fully established.	Ticlopidine	47-58	purinergic receptor P2Y12	Homo sapiens	0-7
12945880-7	2003	In unstable angina patients, plasma levels of TF, TFPI and TFPI/FXa were more efficiently reduced by adjunct ticlopidine therapy compared with adjunct coumadin/dipyridamole.	Ticlopidine	109-120	coagulation factor III, tissue factor	Homo sapiens	46-48
12945880-7	2003	In unstable angina patients, plasma levels of TF, TFPI and TFPI/FXa were more efficiently reduced by adjunct ticlopidine therapy compared with adjunct coumadin/dipyridamole.	Ticlopidine	109-120	tissue factor pathway inhibitor	Homo sapiens	50-54
12945880-7	2003	In unstable angina patients, plasma levels of TF, TFPI and TFPI/FXa were more efficiently reduced by adjunct ticlopidine therapy compared with adjunct coumadin/dipyridamole.	Ticlopidine	109-120	tissue factor pathway inhibitor	Homo sapiens	59-63
12945880-7	2003	In unstable angina patients, plasma levels of TF, TFPI and TFPI/FXa were more efficiently reduced by adjunct ticlopidine therapy compared with adjunct coumadin/dipyridamole.	Ticlopidine	109-120	coagulation factor X	Homo sapiens	64-67
12945880-8	2003	These data suggest reduced release of circulating TF by combined anti-platelet therapy with ticlopidine and aspirin after coronary artery stenting, which may-contribute to the lower incidence of subacute stent thrombosis previously observed.	Ticlopidine	92-103	coagulation factor III, tissue factor	Homo sapiens	50-52
12698015-2	2003	Clopidogrel and ticlopidine are adenosine diphosphate (ADP)-receptor antagonists that inhibit ADP-induced fibrinogen binding to platelets, a necessary step in the platelet aggregation process.	Ticlopidine	16-27	fibrinogen beta chain	Homo sapiens	106-116
12721102-14	2003	Furafylline (a CYP1A2 inhibitor) and ketoconazole (a CYP3A4 inhibitor) significantly decreased the rate of promazine 5-sulphoxidation, while furafylline and ticlopidine (a CYP2C19 inhibitor) significantly decreased the rate of promazine N-demethylation in human liver microsomes.	Ticlopidine	157-168	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	172-179
14610915-4	2003	P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo).	Ticlopidine	139-150	purinergic receptor P2Y12	Homo sapiens	0-5
14610915-4	2003	P2Y12 inhibits adenylyl cyclase through a glycoprotein i (Gi)-dependent pathway, and is the target of the clinically used thienopyridines, ticlopidine (Ticlid, F. Hoffman-La Roche) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Synthelabo).	Ticlopidine	152-158	purinergic receptor P2Y12	Homo sapiens	0-5
12891293-3	2003	AIM: To study changes of parameters of fibrinolysis during short term use of ticlopidine and clopidogrel in NSTEACS patients treated with aspirin and antithrombin.	Ticlopidine	77-88	serpin family C member 1	Homo sapiens	150-162
14529392-6	2003	Ticlopidine and clopidogrel are irreversible P2Y12 antagonists and have been repeatedly proven as clinical antithrombotic agents.	Ticlopidine	0-11	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	45-50
14593356-1	2003	Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].	Ticlopidine	87-98	von Willebrand factor	Homo sapiens	40-61
12891293-9	2003	Compared with their controls ticlopidine treated patients on day 7 had less pronounced lowering of PAI activity (13.6 and 8.2 U/l, p<0.05) and lower D-dimer concentration (515 and 770 ng/ml, respectively, p<0.05).	Ticlopidine	29-40	serpin family E member 1	Homo sapiens	99-102
14593356-4	2003	AIM: To study changes of markers of coagulation and platelet activation during short term use of ticlopidine and clopidogrel in NSTEACS patients treated with aspirin and antithrombin.	Ticlopidine	97-108	serpin family C member 1	Homo sapiens	170-182
12891293-12	2003	CONCLUSION: Compared with controls the use of ticlopidine in patients with NSTEACS treated with aspirin and UFH was associated with less pronounced lowering of PAI activity and lower level of D-dimer.	Ticlopidine	46-57	serpin family E member 1	Homo sapiens	160-163
14593356-9	2003	Compared with their controls ticlopidine treated patients in 7 days after ticlopidine discontinuation had lower levels of TAT (2.77 and 3.61 ng/ml, r<0.05) and fibrinogen (3.16 and 3.84 g/l, r<0.05).	Ticlopidine	29-40	fibrinogen beta chain	Homo sapiens	163-173
14593356-9	2003	Compared with their controls ticlopidine treated patients in 7 days after ticlopidine discontinuation had lower levels of TAT (2.77 and 3.61 ng/ml, r<0.05) and fibrinogen (3.16 and 3.84 g/l, r<0.05).	Ticlopidine	74-85	fibrinogen beta chain	Homo sapiens	163-173
12421153-9	2002	An immunoglobulin (Ig) G autoantibody to the vWF-cleaving metalloprotease is found transiently in many adult patients with acquired acute idiopathic, recurrent, and ticlopidine/clopidogrel-associated TTP.	Ticlopidine	165-176	von Willebrand factor	Homo sapiens	45-48
14593356-10	2003	The level of vWF in ticlopidine treated patients was lower relative to control group on days 3 (163 and 186%, r<0.05) and 14 (144 and 173%, p<0.01).	Ticlopidine	20-31	von Willebrand factor	Homo sapiens	13-16
14593356-13	2003	CONCLUSION: Short term use of ticlopidine in patients with NSTEACS treated with aspirin and unfractionated heparin was associated with lower levels of TAT and fibrinogen (relative to control group) on day 14.	Ticlopidine	30-41	fibrinogen beta chain	Homo sapiens	159-169
14593356-14	2003	This could be interpreted as delayed effect of ticlopidine on thrombin activity.	Ticlopidine	47-58	coagulation factor II, thrombin	Homo sapiens	62-70
14593356-15	2003	Both ticlopidine and clopidogrel used in regimes with loading doses in NSTEACS patients treated with aspirin and antithrombin prevented acute phase elevation of vWF.	Ticlopidine	5-16	serpin family C member 1	Homo sapiens	113-125
14593356-15	2003	Both ticlopidine and clopidogrel used in regimes with loading doses in NSTEACS patients treated with aspirin and antithrombin prevented acute phase elevation of vWF.	Ticlopidine	5-16	von Willebrand factor	Homo sapiens	161-164
11886490-0	2002	Simple plasma exchange reduced autoantibody to von Willebrand factor-cleaving protease in a Japanese man with ticlopidine-associated thrombotic thrombocytopenic purpura.	Ticlopidine	110-121	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	47-86
12197605-2	2002	The lymphocyte stimulation test by ticlopidine was positive and bronchoalveolar lavage fluid showed an increase in lymphocytes and a decrease in the CD4+/8+ ratio, suggesting potentially undesirable side effects of ticlopidine.	Ticlopidine	215-226	CD4 molecule	Homo sapiens	149-152
12105349-8	2002	The use of ticlopidine was associated with a significant risk reduction among patients with lower (86%, P=0.0159) and middle (69%, P<0.0001) levels of CRP, whereas a nonsignificant excess risk (27%, P=0.3896) was evident among those with the highest levels.	Ticlopidine	11-22	C-reactive protein	Homo sapiens	154-157
12138269-0	2002	Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis.	Ticlopidine	10-35	erythropoietin	Homo sapiens	39-53
12138269-1	2002	BACKGROUND/AIMS: A recent observation that antiplatelet-aggregation drugs, including ticlopidine hydrochloride, may prevent erythropoietin (EPO)-induced rise in blood pressure in hemodialysis (HD) patients remains a subject of particular interest.	Ticlopidine	85-110	erythropoietin	Homo sapiens	124-138
12138269-1	2002	BACKGROUND/AIMS: A recent observation that antiplatelet-aggregation drugs, including ticlopidine hydrochloride, may prevent erythropoietin (EPO)-induced rise in blood pressure in hemodialysis (HD) patients remains a subject of particular interest.	Ticlopidine	85-110	erythropoietin	Homo sapiens	140-143
12138269-2	2002	The aim of the present study was to determine the effect of ticlopidine hydrochloride on EPO-induced rise in blood pressure of HD patients with special reference to blood levels of vasoactive substances.	Ticlopidine	60-85	erythropoietin	Homo sapiens	89-92
12138269-10	2002	CONCLUSION: The findings suggest that the preventive effect of ticlopidine hydrochloride on EPO-induced rise in blood pressure may partly be related to the enhancement of NO production in patients on maintenance HD.	Ticlopidine	63-88	erythropoietin	Homo sapiens	92-95
12121059-3	2002	Clopidogrel is a ticlopidin-related antiplatelet drug, with the same mechanism of action; it reduces the expression of the glycoprotein IIb/IIIa, the fibrinogen receptor on the platelet surface.	Ticlopidine	17-27	fibrinogen beta chain	Homo sapiens	150-160
11818464-5	2002	An IgG autoantibody to the vWf-cleaving metalloprotease is found transiently in many adult patients with acute idiopathic, recurrent, and ticlopidine/clopidogrel-associated TTP.	Ticlopidine	138-149	von Willebrand factor	Homo sapiens	27-30
12402518-5	2002	Incubating PMNL in PRP increased the antiaggregant effect of both aspirin (IC50 5.09-fold lower) and ticlopidine (IC50 10.16-fold lower).	Ticlopidine	101-112	prion protein	Homo sapiens	19-22
11858494-0	2002	Ticlopidine inhibits the prothrombotic effects of thrombopoietin and ameliorates survival after supralethal total body irradiation.	Ticlopidine	0-11	thrombopoietin	Mus musculus	50-64
11858494-5	2002	These effects of thrombopoietin on platelet activation and consumption were reduced when mice were pretreated with ticlopidine.	Ticlopidine	115-126	thrombopoietin	Mus musculus	17-31
11858494-7	2002	In summary, thrombopoietin induces long term-mortality of irradiated mice probably through platelet-mediated thrombosis and thus, ticlopidine efficiently counteracts these adverse effects of thrombopoietin.	Ticlopidine	130-141	thrombopoietin	Mus musculus	191-205
11831843-0	2002	Granulocyte colony stimulating factor treatment for delayed recovery of ticlopidine-related neutropenia.	Ticlopidine	72-83	colony stimulating factor 3	Homo sapiens	0-37
12097830-0	2002	The anti-platelet agent, ticlopidine, upregulates interleukin-1-Beta-stimulated nitric oxide production in cultured rat vascular smooth muscle cells.	Ticlopidine	25-36	interleukin 1 beta	Rattus norvegicus	50-68
12097830-6	2002	RESULTS: Ticlopidine enhanced interleukin-1beta (IL-1beta)-induced nitrite production in a dose- and time-dependent manner.	Ticlopidine	9-20	interleukin 1 beta	Rattus norvegicus	30-47
12097830-6	2002	RESULTS: Ticlopidine enhanced interleukin-1beta (IL-1beta)-induced nitrite production in a dose- and time-dependent manner.	Ticlopidine	9-20	interleukin 1 beta	Rattus norvegicus	49-57
12097830-8	2002	IL-1beta alone stimulated both intracellular cAMP and cGMP contents, and the addition of ticlopidine further enhanced their contents.	Ticlopidine	89-100	interleukin 1 beta	Rattus norvegicus	0-8
12097830-9	2002	KT 5720, a selective inhibitor of protein kinase A, but not KT 5823, a selective inhibitor of protein kinase G, abolished the enhancement of IL-1beta-induced nitrite production by ticlopidine.	Ticlopidine	180-191	interleukin 1 beta	Rattus norvegicus	141-149
12097830-11	2002	CONCLUSION: We concluded that ticlopidine enhanced the IL-1beta-induced NO production via cAMP and subsequent activation of protein kinase A in cultured rat VSMC.	Ticlopidine	30-41	interleukin 1 beta	Rattus norvegicus	55-63
11674857-0	2001	Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation.	Ticlopidine	11-22	von Willebrand factor	Homo sapiens	26-47
11674857-6	2001	Binding experiments also revealed that the shear-induced vWF binding to platelets was significantly inhibited by ticlopidine, and less significantly by aspirin, although other indicators of platelet activation, such as shear-induced P-selectin expression and GP Ibalpha translocation were not influenced by either ticlopidine or aspirin.	Ticlopidine	113-124	von Willebrand factor	Homo sapiens	57-60
11674857-6	2001	Binding experiments also revealed that the shear-induced vWF binding to platelets was significantly inhibited by ticlopidine, and less significantly by aspirin, although other indicators of platelet activation, such as shear-induced P-selectin expression and GP Ibalpha translocation were not influenced by either ticlopidine or aspirin.	Ticlopidine	314-325	von Willebrand factor	Homo sapiens	57-60
11674857-7	2001	We demonstrate here that platelet aggregation mediated by von Willebrand factor (vWF) under a high shear rate of 10800 s(-1) cannot be stabilized and that dissociation occurs readily when ADP receptor stimulation is blocked by continuous intake of ticlopidine, indicating that these effects on platelet thrombus formation may contribute to the in vivo antithrombotic effects of ticlopidine.	Ticlopidine	248-259	von Willebrand factor	Homo sapiens	58-79
11674857-7	2001	We demonstrate here that platelet aggregation mediated by von Willebrand factor (vWF) under a high shear rate of 10800 s(-1) cannot be stabilized and that dissociation occurs readily when ADP receptor stimulation is blocked by continuous intake of ticlopidine, indicating that these effects on platelet thrombus formation may contribute to the in vivo antithrombotic effects of ticlopidine.	Ticlopidine	248-259	von Willebrand factor	Homo sapiens	81-84
11674857-7	2001	We demonstrate here that platelet aggregation mediated by von Willebrand factor (vWF) under a high shear rate of 10800 s(-1) cannot be stabilized and that dissociation occurs readily when ADP receptor stimulation is blocked by continuous intake of ticlopidine, indicating that these effects on platelet thrombus formation may contribute to the in vivo antithrombotic effects of ticlopidine.	Ticlopidine	378-389	von Willebrand factor	Homo sapiens	81-84
11580286-0	2001	Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	62-82
11672762-5	2001	Platelet fibrinogen binding and P-selectin expression were significantly lower in patients treated with ticlopidine but not with aspirin than in those not treated with any antiplatelet agent, and were lowest in those treated with both ticlopidine and aspirin.	Ticlopidine	104-115	fibrinogen beta chain	Homo sapiens	9-19
11672762-5	2001	Platelet fibrinogen binding and P-selectin expression were significantly lower in patients treated with ticlopidine but not with aspirin than in those not treated with any antiplatelet agent, and were lowest in those treated with both ticlopidine and aspirin.	Ticlopidine	104-115	selectin P	Homo sapiens	32-42
11672762-5	2001	Platelet fibrinogen binding and P-selectin expression were significantly lower in patients treated with ticlopidine but not with aspirin than in those not treated with any antiplatelet agent, and were lowest in those treated with both ticlopidine and aspirin.	Ticlopidine	235-246	fibrinogen beta chain	Homo sapiens	9-19
11672762-5	2001	Platelet fibrinogen binding and P-selectin expression were significantly lower in patients treated with ticlopidine but not with aspirin than in those not treated with any antiplatelet agent, and were lowest in those treated with both ticlopidine and aspirin.	Ticlopidine	235-246	selectin P	Homo sapiens	32-42
11580286-1	2001	Experiments using recombinant yeast-expressed human liver cytochromes P450 confirmed previous literature data indicating that ticlopidine is an inhibitor of CYP 2C19.	Ticlopidine	126-137	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	157-165
11721975-0	2001	Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity.	Ticlopidine	0-11	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	89-128
11580286-2	2001	The present studies demonstrated that ticlopidine is selective for CYP 2C19 within the CYP 2C subfamily.	Ticlopidine	38-49	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	67-75
11580286-3	2001	UV-visible studies on the interaction of a series of ticlopidine derivatives with CYP 2C19 showed that ticlopidine binds to the CYP 2C19 active site with a K(s) value of 2.8 +/- 1 microM.	Ticlopidine	53-64	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	82-90
11580286-3	2001	UV-visible studies on the interaction of a series of ticlopidine derivatives with CYP 2C19 showed that ticlopidine binds to the CYP 2C19 active site with a K(s) value of 2.8 +/- 1 microM.	Ticlopidine	53-64	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	128-136
11580286-3	2001	UV-visible studies on the interaction of a series of ticlopidine derivatives with CYP 2C19 showed that ticlopidine binds to the CYP 2C19 active site with a K(s) value of 2.8 +/- 1 microM.	Ticlopidine	103-114	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	82-90
11580286-3	2001	UV-visible studies on the interaction of a series of ticlopidine derivatives with CYP 2C19 showed that ticlopidine binds to the CYP 2C19 active site with a K(s) value of 2.8 +/- 1 microM.	Ticlopidine	103-114	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	128-136
11580286-5	2001	Ticlopidine is oxidized by CYP 2C19 with formation of two major metabolites, the keto tautomer of 2-hydroxyticlopidine (1) and the dimers of ticlopidine S-oxide (TSOD) (V(max) = 13 +/- 2 and 0.4 +/- 0.1 min(-1)).	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	27-35
11580286-6	2001	During this oxidation, CYP 2C19 was inactivated; the rate of its inactivation was time and ticlopidine concentration dependent.	Ticlopidine	91-102	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	23-31
11580286-8	2001	It occurs in parralel with CYP 2C19-catalyzed oxidation of ticlopidine, is inhibited by an alternative well-known substrate of CYP 2C19, omeprazole, and correlates with the covalent binding of ticlopidine metabolite(s) to proteins.	Ticlopidine	59-70	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	27-35
11580286-8	2001	It occurs in parralel with CYP 2C19-catalyzed oxidation of ticlopidine, is inhibited by an alternative well-known substrate of CYP 2C19, omeprazole, and correlates with the covalent binding of ticlopidine metabolite(s) to proteins.	Ticlopidine	59-70	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	127-135
11580286-8	2001	It occurs in parralel with CYP 2C19-catalyzed oxidation of ticlopidine, is inhibited by an alternative well-known substrate of CYP 2C19, omeprazole, and correlates with the covalent binding of ticlopidine metabolite(s) to proteins.	Ticlopidine	193-204	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	27-35
11580286-8	2001	It occurs in parralel with CYP 2C19-catalyzed oxidation of ticlopidine, is inhibited by an alternative well-known substrate of CYP 2C19, omeprazole, and correlates with the covalent binding of ticlopidine metabolite(s) to proteins.	Ticlopidine	193-204	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	127-135
11580286-10	2001	The effects of ticlopidine on CYP 2C19 are very analogous with those previously described for the inactivation of CYP 2C9 by tienilic acid.	Ticlopidine	15-26	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	30-38
11580286-10	2001	The effects of ticlopidine on CYP 2C19 are very analogous with those previously described for the inactivation of CYP 2C9 by tienilic acid.	Ticlopidine	15-26	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	114-121
11580286-11	2001	This suggests that a similar electrophilic intermediate, possibly a thiophene S-oxide, is involved in the inactivation of CYP 2C19 and CYP 2C9 by ticlopidine and tienilic acid, respectively.	Ticlopidine	146-157	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	122-130
11580286-11	2001	This suggests that a similar electrophilic intermediate, possibly a thiophene S-oxide, is involved in the inactivation of CYP 2C19 and CYP 2C9 by ticlopidine and tienilic acid, respectively.	Ticlopidine	146-157	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	135-142
11580286-13	2001	Importantly, ticlopidine is the first selective mechanism-based inhibitor of human liver CYP 2C19 and should be a new interesting tool for studying the topology of the active site of CYP 2C19.	Ticlopidine	13-24	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	89-97
11580286-13	2001	Importantly, ticlopidine is the first selective mechanism-based inhibitor of human liver CYP 2C19 and should be a new interesting tool for studying the topology of the active site of CYP 2C19.	Ticlopidine	13-24	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	183-191
11721975-10	2001	Thus, it was concluded that the patient developed TTP by producing an inhibitory autoantibody against vWF-CPase activity that was presumably triggered by Tc administration.	Ticlopidine	154-156	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	102-111
11416985-6	2001	Recently it is found that vWF protease is deficient in hereditary TTP, intermittent relapsing TTP, idiopathic acute TTP and ticlopidine- and clopidogrel-induced TTP, but normal in hemolytic uremic syndrome and organ transplantation-related thrombotic microangiopathy.	Ticlopidine	124-135	von Willebrand factor	Homo sapiens	26-29
11454254-3	2001	The thienopyridines, ticlopidine and clopidogrel, act, via metabolites, on the platelet ADP receptor subtype now designated P2Y(12 )(formerly P(2T), P2T (AC), P2Y (ADP) or P2Y(cyc)) and these agents have proven clinical efficacy.	Ticlopidine	21-32	purinergic receptor P2Y12	Homo sapiens	159-168
11454254-3	2001	The thienopyridines, ticlopidine and clopidogrel, act, via metabolites, on the platelet ADP receptor subtype now designated P2Y(12 )(formerly P(2T), P2T (AC), P2Y (ADP) or P2Y(cyc)) and these agents have proven clinical efficacy.	Ticlopidine	21-32	purinergic receptor P2Y12	Homo sapiens	172-180
11353854-6	2001	Although both aspirin and ticlopidine markedly suppressed platelet aggregation, only ticlopidine impaired gastric ulcer healing and angiogenesis as well as reversing the ulcer-associated changes in serum levels of VEGF and endostatin.	Ticlopidine	85-96	vascular endothelial growth factor A	Rattus norvegicus	214-218
11413167-4	2001	P2Y12 has been shown to be the target of the thienopyridine drugs, ticlopidine and clopidogrel.	Ticlopidine	67-78	purinergic receptor P2Y, G-protein coupled 12	Mus musculus	0-5
11416985-8	2001	Antibodies against vWF protease are present in intermittent relapsing TTP, idiopathic acute TTP, and ticlopidine-induced TTP.	Ticlopidine	101-112	von Willebrand factor	Homo sapiens	19-22
11426486-4	2001	Levels of active TGF-beta1 were elevated in acute but not convalescent phases of TTP/sporadic HUS, as well as TTP associated with human immunodeficiency virus infection and use of the anti-platelet drug ticlopidine.	Ticlopidine	203-214	transforming growth factor beta 1	Homo sapiens	17-26
11181505-9	2001	The metabolic activities of CYP2C9 and CYP2C19 were confirmed by inhibition by sulfaphenazole for CYP2C9 and ticlopidine for CYP2C19.	Ticlopidine	109-120	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	28-34
11181505-9	2001	The metabolic activities of CYP2C9 and CYP2C19 were confirmed by inhibition by sulfaphenazole for CYP2C9 and ticlopidine for CYP2C19.	Ticlopidine	109-120	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	39-46
11181505-9	2001	The metabolic activities of CYP2C9 and CYP2C19 were confirmed by inhibition by sulfaphenazole for CYP2C9 and ticlopidine for CYP2C19.	Ticlopidine	109-120	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	125-132
11245644-2	2001	The role of enhanced antiplatelet protection through pretreatment with the platelet ADP-receptor antagonist ticlopidine in preventing both the early and late complications of coronary stenting has not previously been explored.	Ticlopidine	108-119	purinergic receptor P2Y12	Homo sapiens	75-96
17903802-9	2001	Blood flow in the frontal white matter showed a significant negative correlation with P300 latency before and after replacement of ticlopidine with cilostazol.	Ticlopidine	131-142	E1A binding protein p300	Homo sapiens	86-90
11764927-1	2001	Mechanism-based inactivation of CYP 2C19 by ticlopidine.	Ticlopidine	44-55	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	32-40
11100896-0	2000	Von Willebrand"s factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect.	Ticlopidine	101-112	von Willebrand factor	Homo sapiens	0-23
11460508-10	2001	Several drugs are known to influence fibrinogen levels, the most studied of which are platelet aggregation inhibiting drugs, such as ticlopidine, and the lipid lowering fibric acid derivatives (fibrates).	Ticlopidine	133-144	fibrinogen beta chain	Homo sapiens	37-47
11192941-1	2000	We propose that anti-platelet thienopyridines, such as ticlopidine or clopidogrel, are thrombolytic owing to endothelial release of prostacyclin (PGI2) and tissue plasminogen activator (t-PA).	Ticlopidine	55-66	plasminogen activator, tissue type	Rattus norvegicus	156-190
11192941-7	2000	Thrombolytic action of ticlopidine was accompanied by a rise in 6!keto-PGF1alpha blood levels from 0.42 +/- 0.10 to 1.58 +/- 0.29 ng x ml(-1) and t-PA antigen plasma levels from 4.70 +/- 1.00 to 12.90 +/- 1.15 ng x ml(-1) (n = 7).	Ticlopidine	23-34	plasminogen activator, tissue type	Rattus norvegicus	146-150
11100896-6	2000	Similarly, vWF concentration in the cell coculture supernatant showed the greatest reduction (from 0.22 to 0.11 mg/mL) following the addition of ticlopidine.	Ticlopidine	145-156	von Willebrand factor	Homo sapiens	11-14
10859143-5	2000	The oxidation products of ticlopidine by the combination of myeloperoxidase and hydrogen peroxide were the same as those by HOCl: dehydrogenated ticlopidine and 2-chloroticlopidine.	Ticlopidine	26-37	myeloperoxidase	Homo sapiens	60-75
10966553-7	2000	In contrast, ticlopidine marginally suppressed TRAP-mediated platelet activation at times when maximal effects on ADP-mediated platelet aggregation were evident.	Ticlopidine	13-24	TRAP	Homo sapiens	47-51
10859143-6	2000	A neutrophil-derived reactive metabolite of ticlopidine was trapped with GSH and the same ticlopidine-GSH conjugate was found in both the myeloperoxidase and HOCl systems.	Ticlopidine	90-101	myeloperoxidase	Homo sapiens	138-153
11078261-0	2000	Effect of aspirin and ticlopidine on plasma tissue factor levels in stable and unstable angina pectoris.	Ticlopidine	22-33	coagulation factor III, tissue factor	Homo sapiens	44-57
10759690-0	2000	In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.	Ticlopidine	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	27-42
10759690-0	2000	In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.	Ticlopidine	84-95	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-50
10759690-0	2000	In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.	Ticlopidine	84-95	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	114-121
10759690-0	2000	In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.	Ticlopidine	84-95	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	126-132
10759690-5	2000	RESULTS: TCL was a potent, competitive inhibitor of CYP2C19 (Ki = 1.2 +/- 0.5 microM) and of CYP2D6 (Ki = 3.4 +/- 0.3 microM).	Ticlopidine	9-12	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	52-59
10759690-5	2000	RESULTS: TCL was a potent, competitive inhibitor of CYP2C19 (Ki = 1.2 +/- 0.5 microM) and of CYP2D6 (Ki = 3.4 +/- 0.3 microM).	Ticlopidine	9-12	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	93-99
10759690-7	2000	TCL was also a moderate inhibitor of CYP1A2 (Ki = 49 +/- 19 microM) and a weak inhibitor of CYP2C9 (Ki > 75 microM), but its effect on the activities of CYP2E1 (Ki = 584 +/- 48 microM) and CYP3A (> 1000 microM) was marginal.	Ticlopidine	0-3	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	37-43
10759690-7	2000	TCL was also a moderate inhibitor of CYP1A2 (Ki = 49 +/- 19 microM) and a weak inhibitor of CYP2C9 (Ki > 75 microM), but its effect on the activities of CYP2E1 (Ki = 584 +/- 48 microM) and CYP3A (> 1000 microM) was marginal.	Ticlopidine	0-3	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	92-98
10759690-7	2000	TCL was also a moderate inhibitor of CYP1A2 (Ki = 49 +/- 19 microM) and a weak inhibitor of CYP2C9 (Ki > 75 microM), but its effect on the activities of CYP2E1 (Ki = 584 +/- 48 microM) and CYP3A (> 1000 microM) was marginal.	Ticlopidine	0-3	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	156-162
10759690-7	2000	TCL was also a moderate inhibitor of CYP1A2 (Ki = 49 +/- 19 microM) and a weak inhibitor of CYP2C9 (Ki > 75 microM), but its effect on the activities of CYP2E1 (Ki = 584 +/- 48 microM) and CYP3A (> 1000 microM) was marginal.	Ticlopidine	0-3	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	192-197
10759690-8	2000	CONCLUSIONS: TCL appears to be a broad-spectrum inhibitor of the CYP isoforms, but clinically significant adverse drug interactions are most likely with drugs that are substrates of CYP2C19 or CYP2D6.	Ticlopidine	13-16	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	182-189
10759690-8	2000	CONCLUSIONS: TCL appears to be a broad-spectrum inhibitor of the CYP isoforms, but clinically significant adverse drug interactions are most likely with drugs that are substrates of CYP2C19 or CYP2D6.	Ticlopidine	13-16	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	193-199
11078261-10	2000	When ticlopidine was given for 72 hours, TF levels were similar to normal laboratory values both in stable and unstable patients.	Ticlopidine	5-16	coagulation factor III, tissue factor	Homo sapiens	41-43
10819702-0	2000	Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.	Ticlopidine	126-137	von Willebrand factor	Homo sapiens	23-44
10819702-0	2000	Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.	Ticlopidine	126-137	von Willebrand factor	Homo sapiens	88-109
10819702-2	2000	OBJECTIVE: To investigate whether von Willebrand factor (vWF), which has been associated with idiopathic TTP, is involved in the pathogenesis of ticlopidine-associated TTP.	Ticlopidine	145-156	von Willebrand factor	Homo sapiens	34-55
10819702-2	2000	OBJECTIVE: To investigate whether von Willebrand factor (vWF), which has been associated with idiopathic TTP, is involved in the pathogenesis of ticlopidine-associated TTP.	Ticlopidine	145-156	von Willebrand factor	Homo sapiens	57-60
10819702-12	2000	CONCLUSION: In the patients who developed ticlopidine-associated TTP, autoantibodies to the vWF metalloproteinase were formed; this led to the same type of vWF abnormalities observed in patients with idiopathic acute TTP.	Ticlopidine	42-53	von Willebrand factor	Homo sapiens	92-95
10819702-12	2000	CONCLUSION: In the patients who developed ticlopidine-associated TTP, autoantibodies to the vWF metalloproteinase were formed; this led to the same type of vWF abnormalities observed in patients with idiopathic acute TTP.	Ticlopidine	42-53	von Willebrand factor	Homo sapiens	156-159
10460802-7	1999	Ticlopidine, a potent inhibitor of CYP2C19 and CYP2D6, inhibited bufuralol 1"-hydroxylation by each of these enzymes equipotently.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	35-42
10629575-0	2000	Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.	Ticlopidine	0-11	colony stimulating factor 3	Homo sapiens	60-65
10629575-1	2000	We report here a case of ticlopidine-induced aplastic anemia that responded to G-CSF and review the literature.	Ticlopidine	25-36	colony stimulating factor 3	Homo sapiens	79-84
10629575-10	2000	G-CSF may be helpful in the treatment of ticlopidine-induced aplastic anemia.	Ticlopidine	41-52	colony stimulating factor 3	Homo sapiens	0-5
10668344-12	2000	CONCLUSIONS: The combination of neurological symptoms, thrombocytopenia, fever, renal failure and hemolytic anemia in a patient taking ticlopidine points to a diagnosis of TTP.	Ticlopidine	135-146	ZFP36 ring finger protein	Homo sapiens	172-175
10613611-9	1999	The results are consistent with previous human liver microsome findings that ticlopidine is a potent inhibitor of CYP2C19, a P450 isozyme that is significantly responsible for phenytoin metabolism.	Ticlopidine	77-88	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	114-121
10590186-7	2000	The control group ADP and TRAP, as well as the ticlopidine group TRAP aggregation responses, were equivalent at all time points.	Ticlopidine	47-58	TRAP	Homo sapiens	65-69
10497136-8	1999	We have shown that ticlopidine is a potent inhibitor of CYP2C19 (IC(50) = 4.	Ticlopidine	19-30	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	56-63
10581998-6	1999	Among antiplatelet agents, the logic combination of aspirin and ticlopidine or clopidogrel is already challenging the anti-GP IIb/IIIa orally active compounds.	Ticlopidine	64-75	integrin subunit alpha 2b	Homo sapiens	123-129
10460802-7	1999	Ticlopidine, a potent inhibitor of CYP2C19 and CYP2D6, inhibited bufuralol 1"-hydroxylation by each of these enzymes equipotently.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
10233213-1	1999	AIMS: To examine the effect of ticlopidine administration on the activities CYP2C19 and CYP3 A in vivo using omeprazole as a model substrate.	Ticlopidine	31-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-94
10375966-4	1999	ADP-induced PAC-1 binding to platelets was suppressed in individuals who had taken an oral antiplatelet drug, ticlopidine.	Ticlopidine	110-121	dual specificity phosphatase 2	Homo sapiens	12-17
10494779-0	1999	Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets--definition and detection of ticlopidine/clopidogrel effects.	Ticlopidine	187-198	vasodilator stimulated phosphoprotein	Homo sapiens	41-45
10745577-6	1999	In addition, after ticlopidine treatment, platelets showed a significant fall in expression of all these markers in VVI patients (CD42b p < 0.001, CD61 p < 0.005 and CD62p p< 0.001).	Ticlopidine	19-30	glycoprotein Ib platelet subunit alpha	Homo sapiens	130-135
10745577-6	1999	In addition, after ticlopidine treatment, platelets showed a significant fall in expression of all these markers in VVI patients (CD42b p < 0.001, CD61 p < 0.005 and CD62p p< 0.001).	Ticlopidine	19-30	integrin subunit beta 3	Homo sapiens	150-156
10745577-6	1999	In addition, after ticlopidine treatment, platelets showed a significant fall in expression of all these markers in VVI patients (CD42b p < 0.001, CD61 p < 0.005 and CD62p p< 0.001).	Ticlopidine	19-30	selectin P	Homo sapiens	172-177
10233213-0	1999	Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	46-53
10233213-11	1999	CONCLUSIONS: These findings suggest that ticlopidine inhibited the in vivo activity of CYP2C19, but not, or to a lesser extent CYP3 A4, and that the magnitude of inhibition by ticlopidine is related to the in vivo activity of CYP2C19 before inhibition.	Ticlopidine	41-52	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	87-94
10233213-1	1999	AIMS: To examine the effect of ticlopidine administration on the activities CYP2C19 and CYP3 A in vivo using omeprazole as a model substrate.	Ticlopidine	31-42	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	76-83
10233213-11	1999	CONCLUSIONS: These findings suggest that ticlopidine inhibited the in vivo activity of CYP2C19, but not, or to a lesser extent CYP3 A4, and that the magnitude of inhibition by ticlopidine is related to the in vivo activity of CYP2C19 before inhibition.	Ticlopidine	41-52	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	226-233
10233213-11	1999	CONCLUSIONS: These findings suggest that ticlopidine inhibited the in vivo activity of CYP2C19, but not, or to a lesser extent CYP3 A4, and that the magnitude of inhibition by ticlopidine is related to the in vivo activity of CYP2C19 before inhibition.	Ticlopidine	176-187	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	87-94
10233213-11	1999	CONCLUSIONS: These findings suggest that ticlopidine inhibited the in vivo activity of CYP2C19, but not, or to a lesser extent CYP3 A4, and that the magnitude of inhibition by ticlopidine is related to the in vivo activity of CYP2C19 before inhibition.	Ticlopidine	176-187	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	226-233
9792116-7	1998	The intravenous injection of clopidogrel and ticlopidine caused significant vasomodulatory actions in both femoral and pulmonary ring preparations showing a marked desensitization to serotonin, endothelin-1, serum, and platelet rich plasma/arachidonic acid mixtures.	Ticlopidine	45-56	endothelin 1	Canis lupus familiaris	194-206
9925295-1	1998	Antagonists of the glycoprotein GPIIb/IIIa are a promising class of antithrombotic agents offering potential advantages over present antiplatelet agents (i.e., aspirin and ticlopidine).	Ticlopidine	172-183	integrin subunit alpha 2b	Homo sapiens	32-37
10212499-1	1998	GP IIb/IIIa blockade for stenting offers almost complete inhibition of platelet aggregation and can bridge the delayed onset of action of ticlopidine.	Ticlopidine	138-149	integrin subunit alpha 2b	Homo sapiens	0-6
9727545-4	1998	METHODS AND RESULTS: The objective of this study was to compare the influence of a coadministration of ticlopidine or aspirin on the hemodynamic effects of an ACE inhibitor (enalapril) in patients with chronic heart failure.	Ticlopidine	103-114	angiotensin I converting enzyme	Homo sapiens	159-162
9390115-0	1997	Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	80-87
9657246-1	1998	BACKGROUND: Ticlopidine inhibits platelet aggregation by preventing the binding of fibrinogen to its platelet receptor.	Ticlopidine	12-23	fibrinogen beta chain	Homo sapiens	83-93
9657246-7	1998	RESULTS: Platelet adhesion to plasma and fibrinogen was significantly reduced (about 50%) after treatment with ticlopidine, while adhesion to collagen was not modified.	Ticlopidine	111-122	fibrinogen beta chain	Homo sapiens	41-51
9390115-4	1997	Using human liver microsomes, we showed that ticlopidine is a potent inhibitor of cytochrome P450 2C19, with an estimated inhibition constant (Ki) of 3.7 +/- 0.2 mumol/L.	Ticlopidine	45-56	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	82-102
9390115-5	1997	The influence of ticlopidine on CYP2C9, the other cytochrome P450 isoform that metabolizes phenytoin, is relatively weak, with a calculated Ki of 38.8 +/- 27 mumol/L.	Ticlopidine	17-28	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	32-38
9390115-6	1997	These data suggest that, in this patient, phenytoin toxicity was caused by inhibition of CYP2C19 by ticlopidine, and the data emphasize the importance of CYP2C19 in the metabolism of phenytoin.	Ticlopidine	100-111	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	89-96
9066019-0	1997	Ticlopidine may reduce functional fibrinogen levels by inhibition of MPC incorporation into fibrin.	Ticlopidine	0-11	fibrinogen beta chain	Homo sapiens	34-44
9219328-6	1997	The aortas harvested from both the rabbits and rats treated with clopidogrel or ticlopidine exhibited marked desensitization to the serotonin, endothelin-1, serum and platelet rich plasma/arachidonic acid mixtures.	Ticlopidine	80-91	endothelin 1	Rattus norvegicus	143-155
9180113-7	1997	The percent of P-selectin-positive platelets did not change significantly in the aspirin group but decreased in the ticlopidine group (p = 0.019).	Ticlopidine	116-127	selectin P	Homo sapiens	15-25
8996289-11	1997	RESULTS: Before and during the procedures, there was greater thrombin generation (expressed by higher TAT and F1 + 2 plasma levels) in patients not taking ticlopidine or taking it for < or = 24 h (p < 0.05).	Ticlopidine	155-166	coagulation factor II, thrombin	Homo sapiens	61-69
8865524-0	1996	Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris.	Ticlopidine	42-53	fibrinogen beta chain	Homo sapiens	21-31
8759067-10	1996	In contrast, in patients receiving ticlopidine, expression of LIBS1 decreased (P < .01) and expression of CD62P remained basically unchanged after stenting.	Ticlopidine	35-46	selectin P	Homo sapiens	109-114
8865524-2	1996	Ticlopidine is a drug that inhibits the ADP-induced aggregation of blood platelets and it also has been described that ticlopidine can decrease the plasma fibrinogen level in patients with vascular diseases.	Ticlopidine	0-11	fibrinogen beta chain	Homo sapiens	155-165
8865524-2	1996	Ticlopidine is a drug that inhibits the ADP-induced aggregation of blood platelets and it also has been described that ticlopidine can decrease the plasma fibrinogen level in patients with vascular diseases.	Ticlopidine	119-130	fibrinogen beta chain	Homo sapiens	155-165
8865524-4	1996	The fibrinogen lowering effect of ticlopidine was studied in 26 healthy volunteers, selected on genotype of the Bcl] polymorphism of the fibrinogen beta-gene, and in 26 patients with stable angina pectoris in a double blind, randomized cross-over study.	Ticlopidine	34-45	fibrinogen beta chain	Homo sapiens	4-14
8865524-7	1996	In the healthy volunteers the functional fibrinogen levels had decreased by 0.20 g/l (9%, p = 0.005 using the paired Student l-test) after 4 weeks of 250 mg bid ticlopidine administration, whereas fibrinogen antigen, CRP and TDP levels were not significantly changed.	Ticlopidine	161-172	fibrinogen beta chain	Homo sapiens	41-51
8865524-9	1996	After four weeks 250 mg bid ticlopidine administration the functional fibrinogen levels had decreased by 0.38 g/l (11%, p < 0.005), whereas the fibrinogen antigen, CRP and TDP levels were not significantly changed.	Ticlopidine	28-39	fibrinogen beta chain	Homo sapiens	70-80
8865524-11	1996	Neither in the volunteers nor in the patients was the effect of ticlopidine on the fibrinogen levels associated with the fibrinogen beta-gene polymorphisms.	Ticlopidine	64-75	fibrinogen beta chain	Homo sapiens	83-93
8865524-11	1996	Neither in the volunteers nor in the patients was the effect of ticlopidine on the fibrinogen levels associated with the fibrinogen beta-gene polymorphisms.	Ticlopidine	64-75	fibrinogen beta chain	Homo sapiens	121-131
8865524-12	1996	Therefore, the fibrinogen lowering effect of ticlopidine is likely to be a modulation of the functionality of the molecule and unlikely to be modulated by the acute phase reaction, TDP-levels or the fibrinogen beta-gene polymorphisms.	Ticlopidine	45-56	fibrinogen beta chain	Homo sapiens	15-25
8832488-9	1996	Thrombin-induced aggregation in PRP and washed platelets was significantly reduced after in-vivo treatment with ticlopidine and naftazone.	Ticlopidine	112-123	coagulation factor II	Rattus norvegicus	0-8
8767319-0	1996	[Ticlopidine-induced pancytopenia: therapy of agranulocytosis with granulocyte colony stimulating factor].	Ticlopidine	1-12	colony stimulating factor 3	Homo sapiens	67-104
8832488-9	1996	Thrombin-induced aggregation in PRP and washed platelets was significantly reduced after in-vivo treatment with ticlopidine and naftazone.	Ticlopidine	112-123	proline rich protein 2-like 1	Rattus norvegicus	32-35
7992249-0	1994	How does ticlopidine treatment lower plasma fibrinogen?	Ticlopidine	9-20	fibrinogen beta chain	Homo sapiens	44-54
7485112-0	1995	Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia.	Ticlopidine	61-72	colony stimulating factor 3	Homo sapiens	37-42
7796831-7	1995	Among the oral fibrinogen-lowering drugs, fibrates rank first (e.g. bezafibrate has been reported to reduce increased fibrinogen by as much as 40%, and ticlopidine can induce a reduction of about 15% if fibrinogen was elevated at baseline).	Ticlopidine	152-163	fibrinogen beta chain	Homo sapiens	15-25
7994986-9	1994	The mean delta BTG values of each stroke subtype without ticlopidine treatment, compared with those of controls (0.96 +/- 0.42), were significantly higher except those during the chronic phase of cardioembolic stroke and pronounced variability of delta BTG was noted in most subtypes.	Ticlopidine	57-68	pro-platelet basic protein	Homo sapiens	15-18
7839397-5	1995	The BTG ratio was evaluated with regard to subtype of stroke, time of blood sampling, size of infarct, presence of vascular lesions, and the effect of ticlopidine administration.	Ticlopidine	151-162	pro-platelet basic protein	Homo sapiens	4-7
7839397-10	1995	Use of ticlopidine was partially associated with a lower BTG ratio.	Ticlopidine	7-18	pro-platelet basic protein	Homo sapiens	57-60
8091447-0	1994	Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin.	Ticlopidine	90-101	fibrinogen beta chain	Homo sapiens	17-27
8091447-2	1994	Because fibrinogen plays a central role in platelet aggregation and binding of fibrinogen to platelets is inhibited by ticlopidine, we studied the effect of the plasma fibrinogen concentration on the antiaggregatory action of ticlopidine compared with that of aspirin.	Ticlopidine	119-130	fibrinogen beta chain	Homo sapiens	79-89
8091447-2	1994	Because fibrinogen plays a central role in platelet aggregation and binding of fibrinogen to platelets is inhibited by ticlopidine, we studied the effect of the plasma fibrinogen concentration on the antiaggregatory action of ticlopidine compared with that of aspirin.	Ticlopidine	119-130	fibrinogen beta chain	Homo sapiens	79-89
8091447-3	1994	METHODS: We determined platelet aggregability before and after administration of ticlopidine (200 mg/d) or aspirin (81 mg/d) in 61 stroke patients and correlated the changes with the plasma fibrinogen concentration.	Ticlopidine	81-92	fibrinogen beta chain	Homo sapiens	190-200
8091447-4	1994	RESULTS: In patients receiving ticlopidine, the platelet aggregability induced by 1, 5, and 10 mumol/L adenosine diphosphate significantly decreased compared with aggregability before medication (P < .05), and the reductions had significant negative correlations with the plasma fibrinogen concentration (P < .05).	Ticlopidine	31-42	fibrinogen beta chain	Homo sapiens	282-292
8091447-6	1994	CONCLUSIONS: The relative antiaggregatory effect of ticlopidine is significantly decreased with higher plasma fibrinogen concentrations.	Ticlopidine	52-63	fibrinogen beta chain	Homo sapiens	110-120
7516556-1	1994	G-CSF was applied in three patients with acute, iatrogenic, immunological agranulocytosis (after ticlopidine, thimazol and aminoglutethimide) complicated by severe infections.	Ticlopidine	97-108	colony stimulating factor 2	Homo sapiens	0-5
7517606-0	1994	Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine.	Ticlopidine	67-78	colony stimulating factor 3	Homo sapiens	0-37
8171410-6	1994	When administered orally at the dose of 25 mg/kg, clopidogrel, a potent and selective analogue of ticlopidine, was able to inhibit platelet-induced tissue factor expression whereas aspirin (100 mg/kg, p.o.)	Ticlopidine	98-109	coagulation factor III, tissue factor	Rattus norvegicus	148-161
8165651-8	1994	Thus, ticlopidine facilitates the deaggregation of thrombin-induced human platelet aggregates, most probably because it inhibits the effects of ADP on platelets.	Ticlopidine	6-17	coagulation factor II, thrombin	Homo sapiens	51-59
8187462-12	1994	Ticlopidine hydrochloride, 250 mg two times per day should be considered in patients with ECAD who are unable to tolerate aspirin or who develop cerebrovascular events on aspirin.	Ticlopidine	0-25	cadherin 1	Homo sapiens	90-94
8332965-0	1993	The effect of ticlopidine upon plasma fibrinogen levels in patients undergoing suprapubic prostatectomy.	Ticlopidine	14-25	fibrinogen beta chain	Homo sapiens	38-48
8165651-0	1994	Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin.	Ticlopidine	0-11	coagulation factor II, thrombin	Homo sapiens	75-83
8165651-4	1994	Before and after ticlopidine, platelets stimulated with 1 U/ml thrombin aggregated, released about 80-90% 14C-serotonin and did not deaggregate spontaneously within 5 min from stimulation.	Ticlopidine	17-28	coagulation factor II, thrombin	Homo sapiens	63-71
8322384-2	1993	SUMMARY OF REPORT: Ticlopidine (100 mg BID) was administered for 8 weeks.	Ticlopidine	19-30	BH3 interacting domain death agonist	Homo sapiens	39-42
8322384-7	1993	At 4 and 8 weeks after the initiation of ticlopidine treatment, the hematocrit value and concentration of fibrinogen were also significantly (P < .05) reduced.	Ticlopidine	41-52	fibrinogen beta chain	Homo sapiens	106-116
8332965-1	1993	The mechanisms of the antithrombotic effect of the platelet aggregation inhibiting agent Ticlopidine might include a decrease of the plasma fibrinogen level.	Ticlopidine	89-100	fibrinogen beta chain	Homo sapiens	140-150
8332965-2	1993	The effect of ticlopidine on increased fibrinogen synthesis following trauma, such as surgery, is however not known.	Ticlopidine	14-25	fibrinogen beta chain	Homo sapiens	39-49
1573697-0	1992	The effect of ticlopidine on canine platelets, fibrinogen, and antithrombin III activity.	Ticlopidine	14-25	serpin family C member 1	Canis lupus familiaris	63-79
1436601-4	1992	The correlations between deaggregation, aggregation and beta-thromboglobulin level suggest that the antiaggregant action of the ticlopidine is linked to the inhibition of platelet release reaction.	Ticlopidine	128-139	pro-platelet basic protein	Homo sapiens	56-76
1604445-0	1992	Effects of ticlopidine on monoclonal anti-CD9 antibody-induced platelet aggregation and microparticle generation.	Ticlopidine	11-22	CD9 molecule	Homo sapiens	42-45
1615496-5	1992	The diminished alpha-granule content liberation (beta-thromboglobulin: p less than 0.01; PDGF: p less than 0.01; PF4 not significant) indicates that ticlopidine induces a decrease in platelet activity.	Ticlopidine	149-160	pro-platelet basic protein	Homo sapiens	49-69
1615496-5	1992	The diminished alpha-granule content liberation (beta-thromboglobulin: p less than 0.01; PDGF: p less than 0.01; PF4 not significant) indicates that ticlopidine induces a decrease in platelet activity.	Ticlopidine	149-160	platelet factor 4	Homo sapiens	113-116
1576094-3	1992	It is also known that prolonged administration of N-3 fatty acids, ticlopidine, fibrates, pentoxifylline, or alcohol lower plasma fibrinogen levels.	Ticlopidine	67-78	fibrinogen beta chain	Homo sapiens	130-140
2042443-0	1991	Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors.	Ticlopidine	0-11	fibrinogen beta chain	Homo sapiens	26-36
1665598-2	1991	Ticlopidine significantly inhibited platelet aggregation induced by adenosine diphosphate (ADP), the endoperoxide analogue U46619, collagen or low concentrations of thrombin, but did not inhibit platelet aggregation induced by epinephrine or high concentrations of thrombin.	Ticlopidine	0-11	coagulation factor II, thrombin	Homo sapiens	165-173
1665598-3	1991	Ticlopidine inhibited 125I-fibrinogen binding induced by ADP, U46619 or thrombin (1 U/ml).	Ticlopidine	0-11	coagulation factor II, thrombin	Homo sapiens	72-80
1665598-4	1991	The ADP scavengers apyrase or CP/CPK, added in vitro to platelet suspensions obtained before ticlopidine, caused the same pattern of aggregation and 125I-fibrinogen binding inhibition as did ticlopidine.	Ticlopidine	191-202	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	33-36
1665598-6	1991	After ticlopidine administration, thrombin or U46619, but not ADP, increased the binding rate of the anti-GPII b/III a monoclonal antibody 7E3 to platelets.	Ticlopidine	6-17	coagulation factor II, thrombin	Homo sapiens	34-42
1859515-0	1991	Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.	Ticlopidine	78-89	fibrinogen beta chain	Homo sapiens	12-22
1859515-2	1991	It is also known that ticlopidine decreases fibrinogen levels in plasma.	Ticlopidine	22-33	fibrinogen beta chain	Homo sapiens	44-54
1859515-3	1991	15 PAD patients treated with ticlopidine for 3 months were studied, evaluating the drug"s effect both on maximum walking distance and on fibrinogen.	Ticlopidine	29-40	fibrinogen beta chain	Homo sapiens	137-147
1859515-6	1991	It is proposed that ticlopidine developing the known effect in decreasing the binding of fibrinogen to platelets induces a decrease only of activated fibrinogen.	Ticlopidine	20-31	fibrinogen beta chain	Homo sapiens	89-99
1859515-6	1991	It is proposed that ticlopidine developing the known effect in decreasing the binding of fibrinogen to platelets induces a decrease only of activated fibrinogen.	Ticlopidine	20-31	fibrinogen beta chain	Homo sapiens	150-160
2042443-6	1991	In the ticlopidine group, we recorded a significant 13.14% reduction of the mean fibrinogen level after treatment (390 +/- 63 vs. 449 +/- 97 mg/dl, p less than 0.01).	Ticlopidine	7-18	fibrinogen beta chain	Homo sapiens	81-91
2274920-4	1990	Tcl inhibited ATP secretion in response to ADP and 0.05 u/ml thrombin, but not to higher concentrations of thrombin or to calcium ionophores.	Ticlopidine	0-3	coagulation factor II, thrombin	Homo sapiens	61-69
2147914-2	1990	Ticlopidine and aspirin/dipyridamole, but not xanthinol nicotinate, improved platelet aggregation, reduced beta-thromboglobulin, platelet factor IV and fibrinopeptide A concentrations, and increased antithrombin III concentrations and red blood cell filterability.	Ticlopidine	0-11	pro-platelet basic protein	Homo sapiens	107-127
2147914-2	1990	Ticlopidine and aspirin/dipyridamole, but not xanthinol nicotinate, improved platelet aggregation, reduced beta-thromboglobulin, platelet factor IV and fibrinopeptide A concentrations, and increased antithrombin III concentrations and red blood cell filterability.	Ticlopidine	0-11	serpin family C member 1	Homo sapiens	199-215
2175608-3	1990	Ticlopidine inhibits ADP-induced binding of fibrinogen to platelet glycoprotein GP IIb-IIIa but not shape change and increases deaggregation.	Ticlopidine	0-11	integrin subunit alpha 2b	Homo sapiens	80-86
2175608-5	1990	We studied the effects of ticlopidine (500 mg/day for 8 days) in four healthy male volunteers on washed platelet aggregation induced by 5 microM ADP or thrombin (0.1 units/mL) and potentiated by 1 microM adrenaline (Adr), on basal and 1 microM PGE1-stimulated cAMP levels and on elevation of cytosolic free Ca2+ concentration ([Ca2+]i).	Ticlopidine	26-37	coagulation factor II, thrombin	Homo sapiens	152-160
2175608-6	1990	We found that: (i) ticlopidine inhibits aggregation by ADP but not the potentiation by Adr of ADP-induced aggregation; (ii) ADP, Adr or thrombin decreases cAMP levels raised by PGE1, an effect inhibited by ticlopidine only for ADP and not for Adr or thrombin; and (iii) Ca2+ influx and Ca2+ mobilization from internal stores were not affected.	Ticlopidine	19-30	coagulation factor II, thrombin	Homo sapiens	136-144
2175608-6	1990	We found that: (i) ticlopidine inhibits aggregation by ADP but not the potentiation by Adr of ADP-induced aggregation; (ii) ADP, Adr or thrombin decreases cAMP levels raised by PGE1, an effect inhibited by ticlopidine only for ADP and not for Adr or thrombin; and (iii) Ca2+ influx and Ca2+ mobilization from internal stores were not affected.	Ticlopidine	206-217	coagulation factor II, thrombin	Homo sapiens	136-144
2375765-2	1990	It has been shown that ticlopidine induces a functional defect in the binding of fibrinogen to its platelet membrane receptor.	Ticlopidine	23-34	fibrinogen beta chain	Homo sapiens	81-91
2389831-4	1990	The results showed treatment with ticlopidine improved the neurologic outcome (Hachinski"s Score +36%, p less than 0.03) slightly but significantly (p less than 0.001) increased the average values of the whole blood (+19%) and red cell (+17%) filterability rates and decreased fibrinogen levels (-17%).	Ticlopidine	34-45	fibrinogen beta chain	Homo sapiens	277-287
34697820-6	2021	In the present study, we investigated 2-substituted thienotetrahydropyridine derivatives, structurally related to ticlopidine, as CD39 inhibitors.	Ticlopidine	114-125	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	130-134
34697820-9	2021	The most potent derivative, 32, showed similar CD39-inhibitory potency to ticlopidine, both acting as allosteric inhibitors.	Ticlopidine	74-85	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	47-51
3232130-0	1988	Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease.	Ticlopidine	21-32	fibrinogen beta chain	Homo sapiens	36-46
34503953-3	2021	Three CYP3A4 substrates, midazolam, ticlopidine, and diazepam, display non-Michaelis-Menten kinetics, form multiple primary metabolites, and are sequentially metabolized to secondary metabolites.	Ticlopidine	36-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	6-12
34503953-10	2021	Significance Statement The metabolism of midazolam, ticlopidine, and diazepam by CYP3A4 results in multiple metabolites and sequential metabolism.	Ticlopidine	52-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	81-87
35246464-6	2022	Good estimation of fm,CYP2B6 was not possible in this study due to the poor selectivity of the tested inhibitor (20 microM ticlopidine).	Ticlopidine	123-134	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	22-28
2629467-8	1989	It is interesting that ticlopidine inhibited the Ca2+ influx through the GPIIb/IIIa complex.	Ticlopidine	23-34	integrin subunit alpha 2b	Homo sapiens	73-78
2556779-8	1989	Ticlopidine, by inhibiting fibrinogen binding to the complex, is a potent antiaggregation agent.	Ticlopidine	0-11	fibrinogen beta chain	Homo sapiens	27-37
35579824-6	2022	The relative contributions of different cytochromes P450 (CYPs), mainly CYP3A4 and CYP2B6, involved in esketamine/noresketamine clearance was captured correctly in the IN-PBPK model using the DDI clinical studies of intranasal esketamine with clarithromycin and rifampicin and a published DDI study of oral esketamine with ticlopidine.	Ticlopidine	323-334	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
2791406-7	1989	Aspirin reduced plasma TXB2 but not beta TG or PF4, while ticlopidine reduced beta TG and PF4 but not TXB2.	Ticlopidine	58-69	pro-platelet basic protein	Homo sapiens	78-85
2791406-7	1989	Aspirin reduced plasma TXB2 but not beta TG or PF4, while ticlopidine reduced beta TG and PF4 but not TXB2.	Ticlopidine	58-69	platelet factor 4	Homo sapiens	90-93
2791406-8	1989	On the contrary, aspirin with ticlopidine reduced TXB2 as well as beta TG and PF4.	Ticlopidine	30-41	pro-platelet basic protein	Homo sapiens	66-73
2791406-8	1989	On the contrary, aspirin with ticlopidine reduced TXB2 as well as beta TG and PF4.	Ticlopidine	30-41	platelet factor 4	Homo sapiens	78-81
3232130-4	1988	Consistently lower values of fibrinogen, haematocrit and whole blood viscosity at high and low shear rate levels were found in the ticlopidine group; the intergroup differences were statistically significant at most but not all follow-up examinations.	Ticlopidine	131-142	fibrinogen beta chain	Homo sapiens	29-39
2942757-6	1986	Long term anticoagulation with warfarin plus ticlopidine reduced the beta-TG levels of 19 stage 3 or 4 patients, especially in stage 4 the rate of reduction was marked.	Ticlopidine	45-56	pro-platelet basic protein	Homo sapiens	69-76
3304967-3	1987	Studies in animals and man have demonstrated that ticlopidine is a potent inhibitor of platelet aggregation induced by adenosine diphosphate (ADP), and variably inhibits aggregation due to collagen, adrenaline (epinephrine), arachidonic acid, thrombin, and platelet activating factor.	Ticlopidine	50-61	coagulation factor II, thrombin	Homo sapiens	243-251
3024274-4	1986	Ticlopidine increased the C-AMP level in rat platelets, but aspirin did not.	Ticlopidine	0-11	cathelicidin antimicrobial peptide	Rattus norvegicus	26-31
3304967-5	1987	Ticlopidine also inhibits the release reaction of platelets, prolongs bleeding time, reduces plasma levels of platelet factor 4 and beta-thromboglobulin in patients in whom these proteins are elevated, and may also inhibit platelet adhesion, increase red cell filtrability and decrease whole blood viscosity.	Ticlopidine	0-11	pro-platelet basic protein	Homo sapiens	132-152
6388012-3	1984	Ticlopidine treatment did not significantly improve platelet life-span or factor VIII levels, though it was associated with reduced values of beta TG and PF4.	Ticlopidine	0-11	pro-platelet basic protein	Homo sapiens	142-149
2999489-0	1985	Spin label study of the effect of ticlopidine on platelets.	Ticlopidine	34-45	spindlin 1	Rattus norvegicus	0-4
2999489-4	1985	Ticlopidine inhibited the thrombin-induced aggregation of platelets and caused a slight increase in order parameter and motion parameter in thrombin-aggregated platelets.	Ticlopidine	0-11	coagulation factor II	Rattus norvegicus	26-34
2999489-4	1985	Ticlopidine inhibited the thrombin-induced aggregation of platelets and caused a slight increase in order parameter and motion parameter in thrombin-aggregated platelets.	Ticlopidine	0-11	coagulation factor II	Rattus norvegicus	140-148
4096744-0	1985	Effects of ticlopidine on blood fibrinogen and blood viscosity in peripheral atherosclerotic disease.	Ticlopidine	11-22	fibrinogen beta chain	Homo sapiens	32-42
4096744-5	1985	The fibrinogen levels resulted significantly lowered during 90 days of treatment with ticlopidine, while that was not evident in the nicotinate group.	Ticlopidine	86-97	fibrinogen beta chain	Homo sapiens	4-14
4096744-9	1985	A direct or indirect action of ticlopidine on plasma fibrinogen is suggested.	Ticlopidine	31-42	fibrinogen beta chain	Homo sapiens	53-63
6207465-0	1984	[Effects of ticlopidine on the plasma levels of beta-thromboglobulin and thromboxane B2 in types 1 and 2 diabetics].	Ticlopidine	12-23	pro-platelet basic protein	Homo sapiens	48-68
6207465-0	1984	[Effects of ticlopidine on the plasma levels of beta-thromboglobulin and thromboxane B2 in types 1 and 2 diabetics].	Ticlopidine	12-23	immunoglobulin kappa variable 5-2	Homo sapiens	85-104
6207465-2	1984	Depending on the type of diabetes and the degree of glycaemia, control plasma levels of beta-thromboglobulin and thromboxane B2 were progressively lower after 14, 28 and 42 days of treatment with ticlopidine (500 mg/per day orally), than those encountered at the start of the study.	Ticlopidine	196-207	pro-platelet basic protein	Homo sapiens	88-108
6207465-3	1984	It is concluded that ticlopidine influences plasma levels of beta-thromboglobulin and thromboxane B2 independently of the type and degree of metabolic compensation in diabetes mellitus.	Ticlopidine	21-32	pro-platelet basic protein	Homo sapiens	61-81
3901391-15	1985	Estimated by peak CK-MB and ASAT, infarction size was significantly reduced in the ticlopidine group.	Ticlopidine	83-94	ATP binding cassette subfamily B member 7	Homo sapiens	28-32
3156146-2	1985	We found the following: ticlopidine significantly (P less than 0.001) prolonged the skin bleeding time and impaired the binding of radiolabeled fibrinogen and von Willebrand Factor, the clot retraction and the aggregation of platelets in response to ADP, epinephrine, thrombin, ionophore A23187, collagen, or arachidonic acid.	Ticlopidine	24-35	fibrinogen beta chain	Homo sapiens	144-154
3156146-2	1985	We found the following: ticlopidine significantly (P less than 0.001) prolonged the skin bleeding time and impaired the binding of radiolabeled fibrinogen and von Willebrand Factor, the clot retraction and the aggregation of platelets in response to ADP, epinephrine, thrombin, ionophore A23187, collagen, or arachidonic acid.	Ticlopidine	24-35	coagulation factor II, thrombin	Homo sapiens	268-276
3983900-2	1985	Aggregation studies of twice-washed platelets resuspended in Tyrode solution containing apyrase and 0.35% albumin showed that inhibition by ticlopidine of aggregation induced by ADP, collagen, sodium arachidonate or thrombin persisted after resuspension, as did inhibition of the release of 14C-serotonin from prelabeled platelets.	Ticlopidine	140-151	prothrombin	Oryctolagus cuniculus	216-224
6388012-3	1984	Ticlopidine treatment did not significantly improve platelet life-span or factor VIII levels, though it was associated with reduced values of beta TG and PF4.	Ticlopidine	0-11	platelet factor 4	Homo sapiens	154-157
6592941-0	1984	Ex vivo effects of ticlopidine on human platelets: inhibition of fibrinogen binding by a mechanism independent of thromboxane formation.	Ticlopidine	19-30	fibrinogen beta chain	Homo sapiens	65-75
6740569-0	1984	Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets.	Ticlopidine	14-25	PCNA clamp associated factor	Homo sapiens	29-32
6740569-1	1984	Ticlopidine was incubated in vitro with rabbit or human washed platelets and aggregations were triggered by submaximal concentrations of adenosine-5"-diphosphate (ADP), arachidonic acid (AA) and Paf-acether (platelet-activating factor), the mediators of the three known pathways of platelet activation.	Ticlopidine	0-11	PCNA clamp associated factor	Homo sapiens	195-198
6740569-2	1984	Inhibition of Paf-acether-induced rabbit platelet aggregation was proportional to the concentrations of Ticlopidine used.	Ticlopidine	104-115	PCNA clamp associated factor	Homo sapiens	14-17
6740569-4	1984	Human platelet aggregation induced by Paf-acether was also inhibited by Ticlopidine.	Ticlopidine	72-83	PCNA clamp associated factor	Homo sapiens	38-41
6740569-6	1984	Our results show that Ticlopidine inhibits human and rabbit platelet aggregation triggered by Paf-acether through a mechanism not related to the inhibition of the ADP and prostaglandin pathways.	Ticlopidine	22-33	PCNA clamp associated factor	Homo sapiens	94-97
6208739-0	1984	Beta-thromboglobulin and platelet factor 4 in polycythemia patients treated by ticlopidine.	Ticlopidine	79-90	pro-platelet basic protein	Homo sapiens	0-20
6797089-0	1981	The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets.	Ticlopidine	23-34	fibrinogen beta chain	Homo sapiens	38-48
6197783-7	1983	In many patients with ischemic or obstructive cerebro-vascular diseases treated with anti-platelet drugs such as Aspirin, Dipyridamole, Bencyclane or Ticlopidine, a significant fall in plasma concentration of beta-TG was chronologically demonstrated.	Ticlopidine	150-161	pro-platelet basic protein	Homo sapiens	209-216
6858789-0	1983	Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin.	Ticlopidine	98-109	PCNA clamp associated factor	Homo sapiens	69-72
6858789-1	1983	Platelet aggregation induced by platelet activating factor (PAF) was studied in 95 subjects: 39 controls, 23 patients receiving aspirin and 33 receiving ticlopidine.	Ticlopidine	153-164	PCNA clamp associated factor	Homo sapiens	60-63
6858789-3	1983	The 33 patients treated with ticlopidine showed a highly significant fall of platelet aggregation (p less than 0.001) at the three concentrations of PAF used.	Ticlopidine	29-40	PCNA clamp associated factor	Homo sapiens	149-152
6858789-7	1983	This study demonstrates ticlopidine"s inhibitory action on PAF-induced aggregation and confirms ticlopidine"s role in reducing platelet aggregation by ADP, which has previously been demonstrated.	Ticlopidine	24-35	PCNA clamp associated factor	Homo sapiens	59-62
6797089-10	1981	These results suggest that ticlopidine either inhibits platelet activation and consequently fibrinogen binding, or inhibits the binding directly, presumably by having an effect on the specific configuration of the platelet membrane required for normal fibrinogen binding.	Ticlopidine	27-38	fibrinogen beta chain	Homo sapiens	92-102
6797089-10	1981	These results suggest that ticlopidine either inhibits platelet activation and consequently fibrinogen binding, or inhibits the binding directly, presumably by having an effect on the specific configuration of the platelet membrane required for normal fibrinogen binding.	Ticlopidine	27-38	fibrinogen beta chain	Homo sapiens	252-262
6797089-6	1981	Ticlopidine at final concentrations of 200, 100, 50 and 25 microM inhibited both ADP and adrenaline-induced fibrinogen binding in a dose-dependent manner.	Ticlopidine	0-11	fibrinogen beta chain	Homo sapiens	108-118
7270347-0	1981	[Effects of ticlopidine on blood circulation and thrombin-induced platelet aggregation in experimental diabetic rats- and it"s efficacy for remedy of diabetic retinopathy (author"s transl)].	Ticlopidine	12-23	coagulation factor II	Rattus norvegicus	49-57
33309519-6	2021	The antagonism of platelet P2Y12 receptors by cangrelor, ticagrelor or active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel reduces the ADP-induced platelet aggregation in patients with thrombotic complications of vascular diseases.	Ticlopidine	122-133	purinergic receptor P2Y12	Homo sapiens	27-32
224522-3	1979	Furthermore, Ticlopidine inhibited malondialdehyde formation in platelets induced by thrombin but failed to inhibit that caused by exogenous arachidonic acid.	Ticlopidine	13-24	coagulation factor II	Rattus norvegicus	85-93
148961-2	1977	In order to elucidate the mechanism of fibrinogen kinetic abnormalities different drugs, including heparin, prednisone, ticlopidin, aspirin and indomethacin were administered in 68 patients and their effects evaluated by change in the 311I fibrinogen disappearance rate.	Ticlopidine	120-130	fibrinogen beta chain	Homo sapiens	39-49
30179004-0	2018	HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors.	Ticlopidine	37-48	major histocompatibility complex, class I, A	Homo sapiens	0-5
33993103-6	2021	To verify our method, we detected ADEs with alanine aminotransferase (ALT) elevation in patients receiving aspirin, clopidogrel and ticlopidine.	Ticlopidine	132-143	glutamic--pyruvic transaminase	Homo sapiens	44-68
31732442-0	2020	Reduced multidrug resistance-associated protein 2 in ticlopidine-induced cholestatic liver injury.	Ticlopidine	53-64	ATP binding cassette subfamily C member 2	Homo sapiens	8-49
31764002-11	2020	The aggregating effect of VLCV is more sensitive to ticlopidine than to the clopidogrel suggesting the involvement of ADP/P2Y12/PI3K pathway.	Ticlopidine	52-63	purinergic receptor P2Y12	Homo sapiens	122-127
30922852-5	2019	The nucleoside analogue ticagrelor and active metabolites of the thienopyridine compounds ticlopidine, clopidogrel and prasugrel inhibit platelet P2Y12 receptors and reduce thereby platelet aggregation.	Ticlopidine	90-101	purinergic receptor P2Y12	Homo sapiens	146-151
29513159-0	2019	Elucidating the interaction of ticlopidine with serum albumin and its role in bilirubin displacement in vitro.	Ticlopidine	31-42	albumin	Homo sapiens	54-61
29513159-2	2019	The present study provides a detailed characterization of interaction of ticlopidine with a model transport protein, bovine serum albumin (BSA) as well as an assessment of its bilirubin displacing ability using a multi-spectroscopic approach in combination with isothermal titration calorimetry.	Ticlopidine	73-84	albumin	Homo sapiens	124-137
29513159-8	2019	Additionally, the effect of ticlopidine on bilirubin and albumin interaction was evaluated using the peroxidase method as well as through fluorescence spectroscopy.	Ticlopidine	28-39	albumin	Homo sapiens	57-64
29513159-9	2019	Ticlopidine was found to displace bilirubin from serum albumin.	Ticlopidine	0-11	albumin	Homo sapiens	55-62
29513159-10	2019	Moreover, the binding constant of bilirubin-serum albumin interaction also decreased in presence of ticlopidine.	Ticlopidine	100-111	albumin	Homo sapiens	50-57
30179004-1	2018	The HLA class I allele HLA-A*33:03 is a risk factor for ticlopidine-induced liver injury.	Ticlopidine	56-67	major histocompatibility complex, class I, A	Homo sapiens	23-28
30179004-2	2018	Herein, we show HLA class I-restricted ticlopidine-specific CD8+ T-cell activation in healthy donors expressing HLA-A*33:03.	Ticlopidine	39-50	major histocompatibility complex, class I, A	Homo sapiens	112-117
30179004-3	2018	Cloned CD8+ T-cells proliferated and secreted IFN-gamma in the presence of ticlopidine and autologous antigen presenting cells.	Ticlopidine	75-86	interferon gamma	Homo sapiens	46-55
28726718-7	2017	To illustrate effects of CYP inhibition by trapping agents on reactive intermediate trapping, an example drug (ticlopidine) and trapping agent (NEM) were chosen for further studies.	Ticlopidine	111-122	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	25-28
30091858-3	2018	A mechanistic model was implemented to account for reversible and time-dependent hepatic CYP2B6 inactivation by ticlopidine, which causes elevated S-ketamine exposure in vivo.	Ticlopidine	112-123	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	89-95
30091858-6	2018	Our final model produces biologically plausible output and demonstrates that ticlopidine is a strong inhibitor of CYP2B6 mediated S-ketamine metabolism.	Ticlopidine	77-88	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	114-120
28737446-9	2018	The fm, CYP2B6 values for artemisinin, bupropion, clopidogrel, ketamine, selegiline, sertraline and ticlopidine were 0.24, 0.28, 0.15, 0.45, 0.46, 0.42 and 0.54, respectively, in HLM determined by chemical inhibition method.	Ticlopidine	100-111	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	8-14
28737446-10	2018	The fm, CYP2B6 values for artemisinin, bupropion, clopidogrel, ketamine, selegiline, sertraline and ticlopidine were 0.46, 0.17, 0.15, 0.60, 0.51, 0.66 and 0.77, respectively, in HLM determined by chemical inhibition method in the presence of BSA (0.5% w/v).	Ticlopidine	100-111	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	8-14
28737446-13	2018	Ticlopidine is a time-dependent inhibitor of both CYP2B6 and CYP2C19 that can inhibit the bupropion metabolism by 50-60%.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	50-56
28737446-13	2018	Ticlopidine is a time-dependent inhibitor of both CYP2B6 and CYP2C19 that can inhibit the bupropion metabolism by 50-60%.	Ticlopidine	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	61-68
28726718-8	2017	For the same amount of ticlopidine (1 muM), increasing concentrations of the trapping agent NEM (0.007-40 mM) resulted in a bell-shaped response curve of NEM-trapped ticlopidine S-oxide (TSO-NEM), due to CYP inhibition by NEM.	Ticlopidine	23-34	latexin	Homo sapiens	38-41